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ABSTRACT
Development of the secondary palate (SP) is a complex event despite the small 
area it encompasses. Problems with SP development can lead to a cleft palate, which is 
one of the most common birth disorders. The matrix metalloproteinases (MMPs) are 
required for proper SP development, but a functional role for any one of them remains 
unknown. MMP-25 is a candidate MMP to have a functional role in SP formation as 
genetic scans of the DNA of human cleft palate patients indicate a common mutation at a 
region upstream of the Mmp-25 gene. The purpose of this thesis is to investigate gene 
expression of Mmp-25 in the developing mouse SP, whether it has a functional role in 
mouse SP development and begin to identify factors potentially upstream of Mmp-25 
expression.
Mmp-25 mRNA and protein is found at all SP developmental stages in mice with 
highest expression at embryonic day (E) 13.5 when analyzed by quantitative real-time 
PCR and western blotting. Immunohistochemistry localizes MMP-25 protein primarily to 
the plasma membranes of palate shelf epithelial cells with secondary expression in apical 
mesenchymal cells. Mmp-25 knockdown with siRNA in palatal cultures resulted in a 
significant decrease in palate shelf fusion and persistence of the medial edge epithelium 
in vitro. Mmp-25 mRNA and protein levels are significantly decreased in vitro when 
cultured palate shelves are incubated in growth medium with 5 μg/ml of a TGFβ3-
neutralizing antibody.
Mmp-25 gene expression is highest at E12.5 and E13.5, which corresponds to 
increasing palate shelf growth downward alongside the tongue. Immunohistochemistry 
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localized MMP-25 protein expression predominantly in the epithelium of the palate 
shelves, but also in areas of the mesenchyme that were immediately adjacent to the 
epithelium and apical in location. Knockdown of Mmp-25 expression resulted in palate 
shelf fusion being impaired and significant medial edge epithelium remaining in 
contacted areas. Bioneutralization of TGFβ3 resulted in a significant decrease in Mmp-25 
gene expression. These data suggest a functional role for MMP-25 in mouse SP 
development by removing extra-cellular matrix barriers to increased palate shelf growth 
and place its expression downstream of TGF-β3 signaling. This is the first research to 
present a role for a single MMP in mouse SP development.   
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Research Hypotheses
1. Mmp-25 is constitutively expressed by the medial edge epithelium (MEE) during 
mouse secondary palate (SP) development and involved in palatal shelf fusion 
and midline epithelial seam (MES) degradation. 
2. Knocking down Mmp-25 gene expression results in delayed fusion of the palate 
shelves and persistence of the MEE. 
3. Mmp-25 is primarily regulated by the growth factor, transforming growth factor 
beta 3 (TGFβ3). 
Research Objectives
The first goal was to characterize the temporal and spatial distribution of MMP-25 
expression during the development of the SP in mice. Using quantitative real-time 
polymerase chain reaction (qRT-PCR), western blot analysis and immunohistochemistry 
(IHC) techniques, the expression profile of Mmp-25 and its protein was determined in the 
developing mouse SP.
The second goal of this research was to investigate the role of Mmp-25 during 
mouse SP development using small interfering RNA (siRNA) to knockdown gene 
expression. Establishing a role for Mmp-25 during mouse palatogenesis could provide a 
starting point for MMP research in the SP.
The final goal of this research was to initiate an investigation into the 
transcriptional regulation of Mmp-25 during palatogenesis. Through promoter analysis, 
in vitro palate cultures, qRT-PCR and western blots, some of the molecules controlling 
Mmp-25 expression were determined.
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1. Introduction
1.1 Introduction to Orofacial Clefts
1.1.1 Classifications and Anatomy
Orofacial clefts are birth disorders involving the nose, upper lip and palate. They 
are disfiguring and affect the speech, respiration and eating. Although they can be 
surgically repaired, these operations begin at a very young age and rehabilitation can 
continue into adulthood. Orofacial clefts can be broadly classed into two categories: cleft 
lip with or without cleft palate (CL/P) and cleft palate (CP) alone (Figure 1). Additional 
forms of orofacial clefts exist, but these are rare and usually represent a variation of CL/P 
(Gorlin et al., 2001). The palate, which separates the oropharynx (oral cavity) from the 
nasopharynx (nasal cavity), is comprised of two parts: a primary palate (PP) and SP. The 
PP is located anterior to the SP and consists of the philtrum (indentation) of the upper lip 
and a portion of the maxillary alveolus, in which the four maxillary incisors are set. The 
SP is just posterior to the PP and consists of an anterior ossified hard palate and posterior 
sub-mucous soft palate, which ends with the uvula (Gorlin et al., 2001). The two main 
types of orofacial clefting can be further sub-classified firstly into unilateral clefts, which 
affect one side of the face, or bilateral clefts, which affect both sides of the face; and 
secondly, unilateral or bilateral CL/P and unilateral or bilateral CP may be grouped into 
complete, incomplete or sub-mucous clefts, which would only affect the upper lip or soft 
palate respectively (Shprintzen, 2002). 
1.1.2 Epidemiology
Orofacial clefts are some of the most common birth disorders in humans today. 
Although there are over 400 established syndromes that display CL/P or CP as a clinical 
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Figure 1: Illustration of orofacial clefting variety. Reprinted with permission from 
Children’s Hospital of Wisconsin.
3
symptom, non-syndromic CL/P and CP are still more common (Shprintzen, 2002). 
Worldwide, CL/P occurs in approximately 0.2 to 2.3 births per 1000 and CP in 0.1 to 1.1 
per 1000 births (Mitchell, 2009). There seem to be racial differences in the prevalence of 
CL/P. Those of Asian ancestry have the highest prevalence of CL/P including Native 
American Indians at a rate of approximately 3.6 births per 1000, Japanese at 2.1 births 
per 1000 and Chinese at 1.4 births per 1000. People of European ancestry have a CL/P 
frequency of approximately 0.7 to 1.3 births per 1000 while individuals of African 
ancestry have the lowest frequency of CL/P at 0.3 births per 1000 (Gorlin et al., 2001). 
Despite the variation in CL/P birth frequency between races, there does not seem to be 
such an association for CP. Those of European and African ancestry have CP in 
approximately 0.4 births per 1000 (Gorlin et al., 2001). In Canada, CL/P occurs in 
approximately 1.08 births in 1000 and 0.77 births in 1000 for CP (Health Canada, 2002). 
In Saskatchewan between 1994 and 2003 the prevalence of CL/P was approximately 0.95 
births per 1000 while CP occurred among 0.59 births per 1000 (Winquist et al., 2005). 
CL/P occurs more frequently in males, but CP is more common in females 
(Gorlin et al., 2001). Analyses of genetic studies have indicated CL/P has a hereditary 
association, but is not inherited in a classical, Mendelian fashion. Indeed a monozygotic 
twin only has a 25%-40% chance of developing CL/P if their other twin has it (Mitchell 
and Risch, 1992). A hereditary association for CP also appears to exist, but evidence is 
conflicting; one study indicates first-degree relatives stand only a three percent increased 
chance of developing CP if a parent or sibling also had it (Christensen and Mitchell, 
1996) while another states a three percent increased chance if a sibling has a CP and a 
seven percent increased chance if a parent has a CP (Bernheim et al., 2006). 
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1.1.3 Environmental Risk Factors 
Because development of CL/P and CP is a multi-factorial inheritance, there is a 
complex interaction between multiple genetic loci and environmental factors, thus many 
exogenous factors have been proposed as contributors to CL/P and CP. A variety of 
prescription drugs have been implicated in CL/P and CP. 
Excess retinoic acid, the metabolite of vitamin A, has the strongest association 
with CP. Pregnant women who use isotretinoin (13-cis-retinoic acid) to treat acne in the 
first semester, when the palate is developing, are approximately 26 times more likely to 
have a child with a CP than is another pregnant woman from the general population 
(Mitchell, 2009). An in vitro study showed exposure to excessive retinoic acid at 
embryonic day (E) 10.0 inhibited growth of the palate shelves, which never made contact, 
and exposure at E12.0 resulted in normal palate shelves, but prevented fusion of the 
shelves to each other due to altered cell differentiation where the shelves make contact 
(Abbott et al., 1989). 
Pregnant women who take phenytoin, phenobarbital, valproic acid or 
carbamazepine for any cause (epilepsy, depression, migraines, recurring pain) are at an 
increased risk of having a child with an orofacial cleft. These women are 7.8 and 3.6 
times more likely to have children with CL/P or CP respectively (Mitchell, 2009). The 
usage of corticosteroids in general during the first trimester increases the chances of 
having a child with CL/P or CP by 4.3 and 5.3 times respectively (Mitchell, 2009) and 
usage of prednisone, a type of corticosteroid, has been estimated as increasing a pregnant 
woman’s risk of having a child with an orofacial cleft by 3.4 times (Park-Wyllie et al., 
2000). There is conflicting information linking the benzodiazepines to CL/P and CP. The 
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risk associated with the benzodiazepines has been estimated from no risk to a 1.8 times 
increased chance of an orofacial cleft (Mitchell, 2009).  
A lack of folate/folic acid during the first trimester has been suggested as a causal 
trigger of CL/P and CP, however evidence to support this is inconclusive. One study 
found high dosages of folic acid (6 mg) prevented CL/P and CP (Czeizel et al., 1999); 
another suggested dosages of folic acid found in a typical multi-vitamin were enough to 
reduce risk of CL/P and CP, by 48% and 19% respectively, if women started taking the 
vitamins before getting pregnant or in the first month (Itikala et al., 2001). Yet another 
study reported no link between any sort of increased folate/folic acid intake and a 
reduction in CL/P and CP occurrences (Little et al., 2008). 
Maternal smoking is another inconclusive causal factor in CL/P and CP. One 
study indicates a slight dose-dependent effect of maternal smoking in contributing to CL/
P, but not CP, with light smokers (1-14 cigarettes/day) having an increased risk of 1.09 
times, moderate smokers (15-24 cigarettes/day) at 1.84 times and heavy smokers (25+ 
cigarettes/day) at 1.85 times (Lieff et al., 1999). Another study found an increased risk of 
1.34 and 1.22 times for CL/P and CP respectively (Little et al., 2004). 
Finally, alcohol consumption as the palate is developing has an association with 
the development of CL/P, but not CP, however pregnant women must consume greater 
than five drinks per occasion at least once a week to be 3.4 times more likely than the 
general population to have a child with CL/P (Shaw and Lammer, 1999). Light and 
moderate drinkers had no increased risk of CL/P or CP. The association of so many 
environmental factors with CL/P and CP has to do with the development of the face and 
palate being early in the first trimester before many women realize they are pregnant.   
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1.2 Formation of the Secondary Palate  
1.2.1 Branchial Arch Population
Craniofacial development begins with the migration of the cranial neural crest 
cells (CNCC) into the branchial arches. The CNCC are a set of pluripotent stem cells that 
arise from the neural fold boundary between the neural ectoderm (neural tube) and 
epidermis of the embryonic hindbrain segments, the rhombomeres (Sperber, 2002). 
Expression of Distalless-5 and Pax3 in the neural fold specifies the boundary between the 
neural tube and epidermis and prevent the cells in this region from becoming either 
neural tube or epidermis (Gilbert, 2006). At the same time Distalless-5 and Pax3 induce 
expression of Slug and FoxD3, which specifies cells in the neural fold to become CNCC 
and enables them to migrate ventro-laterally away from the dorsal regions of the 
rhombomeres (Gilbert, 2006). Migration and proliferation of the CNCC populates the 
branchial arches, which are embryonic folds of the future face and neck located ventrally 
to the rhombomeres (Figure 2; Sperber, 2002). The direction of migration of the CNCC 
into the branchial arches is initially determined by expression of the homeobox (HOX) 
genes, which are crucial in establishing the anterior-posterior axis of embryos, as the 
CNCC generally express the same HOX genes as the rhombomeres they originate from 
(Burdi, 2006). The main HOX genes involved in rhombomere, and thus CNCC and 
branchial arch, identity are Hoxa2, -a3, -b2 and -b3 (Trainor and Krumlauf, 2000). 
CNCC from rhombomeres one and two, as well as from the midbrain, populate the first 
branchial arch; CNCC from rhombomere four populate branchial arch two and CNCC 
from rhombomeres six to eight populate branchial arches three and four (Gilbert, 2006). 
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Figure 2: Direction of cranial neural crest cell migration from embryonic mesencephalon 
and rhombencephalon brain segments into the branchial arches. Reprinted with 
permission from Le Douarin, 2004. 
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CNCC from rhombomeres three and five do not contribute to craniofacial development 
(Burdi, 2006).  
1.2.2 Development of the Face
Central to the developing face is the stomodeum, a pit that will be the future 
mouth (Burdi, 2006). Within the stomodeum lies the oropharyngeal membrane, which 
marks the boundary between the endoderm of the future throat and the ectoderm of the 
future mouth before undergoing apoptosis and degrading at 28 days thereby creating a 
continuous tube from mouth to gut (Sperber and Sperber, 2009; Burdi, 2006). Around the 
stomodeum are three primary prominences that will give rise to the face: the frontonasal 
(FNP), the maxillary (MAXP) and the mandibular (MANP; Sperber and Sperber, 2009). 
Although it is CNCC of branchial arch one that give rise to the MAXP and MANP, 
CNCC of the midbrain give rise to the FNP (Gilbert, 2006). The FNP lies atop the 
stomodeum, the MAXP on either side of it and the MANP below it (Figure 3; Sperber, 
2002). The nose forms when nasal pits in the FNP on either side of the face are flanked 
by lateral and median nasal prominences that ring the nasal pits and then grow out from 
the face (Sperber, 2002). Growth and movement of the facial prominences is due to 
migration and proliferation of the cells within them (Burdi, 2006). As the FNP grows 
downward, the nasal pits are brought closer together until the median nasal prominences 
merge with each other and with the medial ends of the MAXP, which has been growing 
up and out towards the center of the face on either side of the primitive mouth (Sperber, 
2002). Fusion of the median nasal prominences with the MAXP and fusion of the 
bilateral MAXP segments together results in the nose, upper jaw, upper lip, cheeks and 
PP being formed (Sperber and Sperber, 2009). The philtrum of the upper lip develops 
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Figure 3: Illustration of embryonic facial prominences and progression of facial 
development. Reprinted with permission from Helms et al., 2005.
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later due to preferential collagen deposition in the middle of the upper lip (Burdi, 2006). 
Movement of the eyes from a lateral to central position is due to the FNP narrowing as 
the nose develops and lateral expansion of the rest of the face (Sperber, 2002). The mouth 
opening narrows as the MAXP and MANP grow towards each other and takes on its 
definitive shape when the two jaw processes fuse (Sperber, 2002). Concurrent to the 
movement and fusion of the facial prominences is the migration and differentiation of 
CNCC from the first branchial arch that did not populate the FNP, MAXP or MANP. 
These cells will form the underlying muscles, skeleton, nerves, blood vessels and 
connective tissue of the face (Burdi, 2006).                           
1.2.3 Development of the Secondary Palate
Development of the SP, or palatogenesis, takes place between E11.5 and E16.0 in 
mice and is critical in gestation weeks six to nine in humans (Burdi, 2006). Development 
of the secondary hard palate and secondary soft palate is slightly different, however the 
similarities between mouse and human SP development make the mouse an excellent 
model animal with which to study palatogenesis. Initially, bilateral palatal processes bud 
from the MAXP within the stomodeum, forming palate shelves, and grow downward 
alongside the tongue (Figure 4; Dudas et al., 2007). Around the end of week eight in 
humans and E14.0 in mice, the tongue will drop due to an increase in stomadeum size 
and the palate shelves will reorient themselves horizontally above it (Sperber, 2002). The 
mechanism behind the sudden elevation of the palate shelves is an increase in fluid 
turgor, due to accumulation of hydrated hyaluronic acid, and asymmetrical proliferation 
in the mesenchyme (Sperber and Sperber, 2009). Once elevated the hard palate shelves 
will grow together and make contact not only with each other along their medial edges, 
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Figure 4: Illustration of the main stages in secondary palate development. Reprinted with 
permission from Dudas et al., 2007.
12
but also with the base of the nasal septum, which has been growing downward from the 
roof of the stomodeum, and the PP, which formed earlier as the median nasal 
prominences fused with the MAXP (Sperber, 2002). Upon making contact, the hard 
palate shelves fuse together via microvilli and proteoglycan attachment on the MEE 
(Burdi, 2006), which creates the MES. Fusion occurs in the medial area of the hard palate 
shelves first and proceeds in a zippering-like manner anteriorly and posteriorly 
simultaneously (Sperber and Sperber, 2009). Degradation of the MES and removal of the 
MEE between the fused hard palate shelves is the final critical step in successful 
palatogenesis. The epithelial cells of the MES may undergo apoptosis, migrate away from 
the seam or, least likely, undergo an epithelial-to-mesenchymal transition (Gibbins et al., 
1999; Vaziri Sani et al., 2005; Xu et al., 2006; Cuervo and Covarrubias, 2004; Jin and 
Ding, 2006). Although evidence regarding the fate of the MES is still conflicting, 
apoptosis of the MEE cells seems to be the primary means through which the MES 
disappears (Dudas et al., 2007). Following degradation of the MES, there is increased 
proliferation in the mesenchyme of the SP to fill the gap left by the MEE. Shortly after 
fusion ossification begins in the anterior, hard SP from primary ossification centers 
located in the maxillae and palatine bones, but does not extend posteriorly into the sub-
mucous, soft SP near the back of the throat (Sperber and Sperber, 2009). Formation of the 
soft SP occurs at the most posterior end of one of the lateral palatal processes while the 
uvula develops from the most posterior end of the other (Burdi, 2006). The two posterior 
ends do not fuse like the hard palate shelves, but rather undergo proliferation in the 
mesenchyme until the two posterior ends have grown together and merged (Burdi, 2006). 
Fusion of the anterior shelves together and merging of the soft SP with the uvula 
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posteriorly as well as fusion to the base of the nasal septum and PP creates a confluent 
SP.           
1.2.4 Genetic Control of Secondary Palate Development
1.2.4.1 Transcription Factors
A variety of transcription factors (TFs) have been implicated as having crucial 
roles in SP development and many are homeobox genes involved in establishing the 
embryonic body pattern. Mouse Lhx8 is a TF containing domains for interacting with 
DNA and regulatory interactions with other proteins (Zhao et al., 1999). Lhx8 is 
expressed exclusively in the mesenchyme of the palate shelves throughout SP 
development with stronger expression near the tips of the palate shelves directly 
underneath the epithelium (Zhang et al., 2002).  Lhx8-/- mice have a CP, which is due to 
the palate shelves never making contact or fusing after elevation, although they exhibit no 
other craniofacial defects (Zhao et al., 1999). Lhx8 expression is detected in the 
mesenchyme of the tooth primordia and its continued expression is dependent on the 
overlying epithelium (Grigoriou et al., 1998) so Lhx8 was proposed to be involved in 
regulating epithelial-mesenchymal interactions during SP development and in its absence 
a CP forms (Zhao et al., 1999). More recent research has suggested human LHX8 plays a 
minor role in contributing to orofacial clefts (Vieira et al., 2005) and no further work has 
been done in mice.
Human TBX22, a TF with conserved DNA-binding T-Box domain, was first 
implicated in a syndromic form of X-linked CP when TBX22 loss-of-function mutations 
were discovered in CP patients (Braybrook et al., 2001). Although linked to a syndromic 
form of CP caused by defects in tongue musculature, it was hypothesized TBX22, and its 
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mouse orthologue Tbx22, were involved in proper development of the SP and disruption 
of their expression could lead to isolated, or non-syndromic, CP (Braybrook et al., 2001; 
Braybrook et al., 2002). Expression of Tbx22 is restricted to the mesenchyme of the 
palate shelves as they bud from the MAXP and is highest at E13.5, but Tbx22 expression 
has been completely down-regulated by E14.5 once the palate shelves have elevated and 
begun to fuse along their medial edges (Braybrook et al., 2002; Bush et al., 2002). In 
addition to temporal regulation, expression of Tbx22 appears to be spatially-regulated as 
its expression is minimal in the anterior SP, but high in the medial and posterior portions 
where it is downstream of  the TF Mn1 (Liu et al., 2008). The tightly-regulated nature of 
Tbx22 expression coupled with its syntenic chromosomal location in the genomes of mice 
and humans has led to more recent genomic investigations in humans that established a 
significant role for TBX22 in CP (Bush et al., 2002; Marçano et al., 2004).        
Hoxa2 is a mouse homeobox transcription factor involved in establishing 
rhombomere, CNCC and branchial arch identity along the anterior-posterior axis (Trainor 
and Krumlauf, 2001). Hoxa2-/- mice also develop a CP; although the palate shelves grow, 
they do not elevate normally, however this is in addition to defects in the skull, ears and 
facial nerves so the CP is believed to be the secondary result of an antecedent defect 
(Gendron-Maguire et al., 1993; Rijli et al., 1993). Indeed, later work demonstrated that in 
Hoxa2-/- mice the hyoglossus muscle, responsible for depressing the tongue during SP 
development, does not form properly and thus the tongue represents a barrier to palate 
shelf contact in Hoxa2-/- mice and a CP forms (Barrow and Capecchi, 1999). The most 
recent work in the developing SP indicates additional roles for Hoxa2 as the central 
figure in numerous signal transduction pathways and could represent novel ways Hoxa2 
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contributes to the formation of CP (Nazarali et al., 2000; Smith and Nazarali, unpublished 
data).   
         Msx1 is another homedomain TF involved in SP development. Msx1-/- mice 
have palate shelves that grow and elevate normally, but do not make contact resulting in a 
CP (Satokata and Maas, 1994). In addition to a CP, these mice also exhibit a complete 
lack of alveolae and teeth and have ear and skull malformations (Satokata and Maas, 
1994). Expression of Msx1 is strictly in the anterior palate shelf mesenchyme with strong 
expression at E12.5 and E13.5, but no results for later developmental stages (Zhang et al., 
2002). CP in Msx1-/- mice is caused by decreased mesenchymal cell proliferation and a 
failure to grow together and make contact around E14.0 as in vitro palatal cultures 
showed palate shelves from Msx1-/- mice retained the ability to fuse normally (Zhang et 
al., 2002). Transgenic studies have shown Msx1 is upstream of bone morphogenetic 
protein 4 (Bmp4) expression, which in turn up-regulates sonic hedgehog (Shh) and Bmp2 
resulting in increased cell proliferation in the palate shelves (Zhang et al., 2002). The 
close family member of Msx1, Msx2, does not appear to play a role in SP development. 
Though Msx2 is expressed in a spatially over-lapping manner and is said to be 
functionally redundant to Msx1, it does not rescue the CP phenotype of Msx1-/- mice 
(Alappat et al., 2003).
There are regional differences in the expression of some TFs in SP development 
due to reciprocal interactions between cells in the anterior, medial and posterior portions 
of the palate shelves (Hilliard et al., 2005). Msx1 expression is only found in the anterior 
palate shelves while expression of Tbx22 and its inducer Mn1 is located only in the 
posterior palate shelves, however regional differences in expression are not static. 
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Expression of the TFs short stature homeobox 2 (Shox2) and mesenchyme homeobox 2 
(Meox2) alters considerably from E12.5 to E14.5; at E12.5 Shox2 expression is found 
only in the anterior-most 25% of the palate shelves while Meox2 expression covers 
approximately 70% of the palate shelf from the posterior end, but by E14.5 Shox2 
expression has expanded to cover 60% of the palate shelf and Meox2 has regressed to the 
posterior-most 25% (Li and Ding, 2007). This anterior regulation of Shox2 expression is 
responsible for Shox2-/- mice developing a very rare CP in which in the soft, posterior SP 
has formed normally, but the hard, anterior SP has a cleft (Yu et al., 2005). Expression of 
the TF Osr2 is restricted to the medial regions of the palate shelves where they initially 
bud from the MAXP and is significantly down-regulated once the shelves elevate (Lan et 
al., 2004). Osr2-/- mice develop a CP due to reduced mesenchymal cell proliferation in the 
medial region, but not anterior or posterior regions, which contributes to a significant 
delay in shelf elevation and lack of contact afterward (Lan et al., 2004).              
1.2.4.2 Growth Factors and Receptors
Growth factors have an integral role in SP development and the most important of 
these are the TGFβ family. There are three secreted members in the TGFβ family of 
growth factors, TGFβ1 to TGFβ3, which bind to the TGFβ receptor type 2 (TβR2) as 
ligands (Dünker and Krieglstein, 2000). This results in dimerization and phosphorylation 
between TβR2 and TβR1, which are receptor tyrosine kinases. The initial targets of 
phosphorylation from the activated TGFβRs are the SMAD proteins; SMAD2 or SMAD3 
are phosphorylated, combine with SMAD4 and translocate to the nucleus resulting in 
alterations of target gene transcription (Dünker and Krieglstein, 2000). Of the three TGFβ 
members, TGFβ2 and TGFβ3 seem to affect SP development the most.
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Mouse lines that have tgfβ2 or tgfβ3 knocked out have a CP. Tgfβ2-/- mice develop 
a CP that results from an inability of the palate shelves to elevate and reorient themselves 
horizontally above the tongue around E14.0 although this phenotype is just one of a wide 
variety of developmental defects (Sanford et al., 1997). Treatment of in vitro palatal 
cultures with exogenous TGFβ2 or TGFβ1 accelerates fusion between the palate shelves, 
although only tgfβ2-/- mice have a CP albeit with less than one-quarter of tgfβ2-/- mice 
displaying the CP (Gehris and Greene, 1992). Expression of tgfβ1 and tgfβ2 is found in 
the MEE and mesenchyme immediately adjacent to the MEE respectively and neither is 
expressed until the palate shelves have elevated above the tongue (Fitzpatrick et al., 
1990). Both in vivo and in vitro work suggest tgfβ1 and tgfβ2 contribute to mouse SP 
development, but tgfβ3 appears to contribute the most. 
Tgfβ3-/- mice develop a CP at nearly 100% levels, although the mice develop 
different types of CP; some have clefting of the anterior portion of the SP, some have 
posterior SP clefting while others show a complete SP cleft (Proetzel et al., 1995). This in 
contrast to tgfβ2-/- mice, which develop the same, complete SP cleft, but display far less 
penetrance of the CP phenotype. Also, the CP in tgfβ3-/- mice is the only developmental 
defect displayed as problems with the airway may be secondary to the CP in tgfβ3-/- mice 
(Proetzel et al., 1995). Expression of tgfβ3 is first found at approximately E13.5 in the 
palate shelf epithelium, but becomes more restricted to the MEE following palate shelf 
elevation before being eliminated once the palate shelves fuse (Fitzpatrick et al., 1990). 
The role of tgfβ3 in SP development appears to be mediating fusion of the palate shelves 
as the shelves of tgfβ3-/- mice make contact with each other, but never fuse and the MEE 
remains at the MES while application of exogenous TGFβ3 completely rescued the 
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defective fusion (Kaartinen et al., 1997). Further analysis into the role of tgfβ3 in palate 
shelf fusion showed just prior to fusion filopodia are formed from the outer cell surfaces 
of the MEE and appear to be coated with proteoglycans to aid in adhesion and fusion of 
the palate shelves, whereas these structures are lacking in the tgfβ3-/- mice. Addition of 
exogenous TGFβ3 to in vitro palatal cultures of tgfβ3-/- mice recovered development of 
the proteoglycan-covered filopodia (Taya et al., 1999). The principal proteoglycan 
induced by TGFβ3 on the filopodia was chondroitin sulfate, which is synthesized and 
secreted just prior to palate shelf fusion and spatially restricted to expression in the MEE 
(Gato et al., 2002). 
The TGFβ3 signal transduction pathway incorporates SMAD2, SMAD3 and 
SMAD4 as intra-cellular mediators of gene transcription and knockdown of Smad2 
expression produces a phenotype similar to tgfβ3-/- mice (Cui et al., 2005) while over-
expression of SMAD2 in the MEE of tgfβ3-/- mice partially recovers a wild-type 
phenotype (Shiomi et al., 2006). As TGFβ3 binds to a heterodimeric receptor complex of 
TβR1 and TβR2 it is no surprise that TβR2 is necessary for proper SP development in 
order to initiate the TGFβ3 pathway. Specific deletion of TβR2 in the CNCC prior to SP 
development results in a complete CP due to decreased proliferation of the palatal 
mesenchyme, however, unlike the tgfβ3-/- mice, these palate shelves are able to fuse when 
their medial edges contact (Ito et al., 2003). Specific deletion of TβR2 solely in the 
epithelium of the palate shelves causes an incomplete CP and persistence of the MES, 
which resembles the inability to fuse or degrade the MES of tgfβ3-/- mice (Xu et al., 
2006). The role of TβR3, long believed to be non-signaling due to lack of a cytoplasmic 
domain, during SP development has been outlined recently. Expression of TβR3 in the 
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SP very closely mimics that of TGFβ3 both temporally and spatially and specific 
knockdown of TβR3 causes a significant delay in palate shelf fusion and decreases intra-
cellular levels of phosphorylated SMAD2 (Nakajima et al., 2007), yet exactly what role 
TβR3 is playing in SP development remains unclear. Taken together it is clear the 
evidence to support a critical role for TGFβ3, its receptors and intra-cellular mediators, 
the SMADs, during SP development is very strong.
The fibroblast growth factor (FGF) family is another group with members 
required for proper SP development. Like the TGFβ3 signaling pathway, the FGF 
signaling pathway depends on dimerization of the FGF receptors (FGFRs) upon ligand 
binding, but then utilizes another signal transduction pathway. The activated FGFR 
tyrosine kinases phosphorylate fibroblast growth factor receptor substrate 2 (FRS2), 
which provides binding sites for proteins that initiate the rat sarcoma (RAS)-mitogen-
activated protein kinase (MAPK) signal transduction pathway that will affect target gene 
transcription (Borland et al., 2001). Mice lacking the IIIb isoform of FGFR2 develop a 
CP, among various other developmental defects (De Moerlooze et al., 2000), as do 
fgf18-/- mice (Liu et al., 2002). A closer examination of the FGF family and its relation to 
SP development revealed fgf10-/- mice, in addition to fgf18-/- and fgfr2b-/- mice, also 
develop a CP and display reduced proliferation in both the epithelium and mesenchyme 
of the palate shelves that results in decreased shelf growth and precludes the shelves from 
elevating (Rice et al., 2004). The roles of fgf10 and fgfr2b illustrate the importance of 
epithelial-mesenchymal interactions in proper SP development. Expression of fgf10 and 
fgfr2b is predominantly found in the mesenchyme immediately adjacent to palatal 
epithelium and in the oral epithelium respectively (Rice et al., 2004). Activation of 
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epithelial FGFR2b by its ligand FGF10, produced in the mesenchyme, increases 
epithelial expression of other signaling molecules, like Sonic Hedgehog (SHH); these 
signaling molecules bind to and activate their receptors back in the palate shelf 
mesenchyme and modulate FGF control over cell proliferation (Rice et al., 2004). 
SHH and members of the bone morphogenetic protein (BMP) family are crucial 
contributors to SP development, however their expression is dependent on TFs and 
growth factors such as MSX1, TGFβ3 and FGF10 (Zhang et al., 2002; Sasaki et al., 
2007; Rice et al., 2004), with which they function in an auto-looping mechanism 
dependent on both molecules (Gritli-Linde, 2007). SHH is a paracrine signaling molecule 
that binds to its receptor patched (PTCH), which relieves repression of another 
membrane-localized protein smoothened (SMO); SMO is internalized from the 
membrane in a vesicle with a protein complex where it participates in a series of 
phosphorylation events that prevent degradation of the glioma-associated oncogene 
homolog (GLI) proteins, which then translocate to the nucleus and affect gene 
transcription (Chari and McDonnell, 2007). The BMPs are a member of the same 
superfamily as the TGFβs and their signal transduction pathway is very similar to that of 
the TGFβs. Binding of a BMP ligand to a type II receptor causes dimerization with a type 
I receptor that leads to phosphorylation and dimerization of SMAD1, SMAD5 or 
SMAD8 with SMAD4, which leads to altered gene transcription (von Bubnoff and Cho, 
2001). 
Expression of SHH is found in the developing SP at all stages, but localized to 
distinct areas of oral epithelium; its receptor, PTCH, is found in the mesenchyme 
immediately adjacent to the epithelium expressing SHH while the other downstream 
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proteins (SMO, GLIs) are expressed widely throughout the palate (Rice et al., 2006). 
Like FGF signaling, SHH signaling is an example of crucial epithelial-mesenchymal 
interactions in the SP while it forms. Shh-/- mice have a CP with palate shelves that fail to 
grow properly or elevate (Rice et al., 2004) and though SHH is produced by the oral 
epithelium of the palate shelves, following stimulation by mesenchymally-produced 
FGF10 (Rice et al., 2004), its signaling target is the mesenchyme, where it drives cell 
proliferation and palate shelf growth through SMO (Lan and Jiang, 2009). One of the 
transcriptional targets in the mesenchyme for SHH is fgf10, which completes the looping 
expression mechanism and will result in further Shh expression thereby driving cell 
proliferation in the mesenchyme of the palate shelves (Lan and Jiang, 2009).
While no CP phenotype has been reported for knockouts of the BMP ligands, 
knocking out the BMP receptor, Bmpr1a, in mice results in bilateral cleft lip with CP 
(Liu et al., 2005) and expression of Bmp4 under the control of the Msx1 promoter rescues 
the CP that develops in Msx1-/- mice (Zhang et al., 2002). BMP expression in the SP is 
part of another looping expression mechanism whereby the TF MSX1 upregulates 
expression of Bmp2 and Bmp4 in the anterior palate shelf mesenchyme and these two 
BMPs then act to upregulate Msx1 expression (Zhang et al., 2002). Expression of Bmp 
expression is localized to palate shelf mesenchyme and the defects associated with 
impaired BMP signaling in the developing SP appear to be caused by reduced 
mesenchymal cell proliferation and impaired palate shelf growth as the palate shelves of 
Bmpr1a-/- mice could still fuse in vitro (Liu et al., 2005).                        
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1.2.4.3 Juxtacrine Interactions
Not only do paracrine interactions such as SHH signaling have an integral role in 
SP development, but also juxtacrine interactions of the Notch signal transduction 
pathway in which ligand and receptor are on two opposing cells contacting each other. In 
this pathway one cell displays the NOTCH1 receptor on its surface while neighbouring 
cells express a ligand for the NOTCH1 receptor; binding of the ligand from one cell to 
the receptor on another triggers proteolysis of the receptor, which then interacts with 
various cytosolic and nuclear proteins to affect gene transcription (Jiang et al., 1998). 
Mice that have had Jag2, a ligand for NOTCH1, knocked out develop a CP and die 
shortly after birth (Jiang et al., 1998). Expression of both Jag2 and Notch1 is found in the 
oral epithelium of the palate shelves and appears to both prevent adhesion of the oral 
epithelium to the tongue epithelium and facilitate adhesion and fusion of the palate 
shelves (Casey et al., 2006). Mouse SP development is under the control of many TFs 
and signaling molecules acting in paracrine and juxtacrine manners, but there is another 
large family of proteins, which seem to play a role in SP development and are not TFs, 
growth factors or any type of signaling molecule; the matrix metalloproteinases.    
1.3 The Matrix Metalloproteinases
1.3.1 Domain Structure
The matrix metalloproteinases (MMPs) are a family of extra-cellular matrix 
(ECM)-degrading enzymes, requiring a zinc atom at their catalytic center to be active, 
which are involved in developmental events as well as the progression of cancers and 
other diseases. There are currently 25 members of the MMP family who share various 
conserved domains (Figure 5). As the MMPs are membrane-localized or exocytosed from 
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Figure 5: Schematic representation of matrix metalloproteinase (MMP) domain structure. 
Minimal domain: MMP-7, -26; simple hemopexin: MMP-1, -3, -8, -10, -12, -13, -18, -19, 
-20, -22, -27; gelatin-binding: MMP-2, -9; furin-activated secreted: MMP-11, -28; 
vitronectin-like insert: MMP-21; transmembrane: MMP-14, -15, -16, -24; GPI-anchored: 
MMP-17, -25; type II transmembrane: MMP-23. Reprinted with permission from 
Egeblad and Werb, 2002. 
cells, all MMPs are initially synthesized with a signal sequence at their amino terminal 
end that will direct the nascent polypeptide into the secretory pathway for processing and 
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eventual export to the cell’s exterior (Murphy and Nagase, 2008). This signal sequence is 
cleaved co-translationally once the polypeptide is in the endoplasmic reticulum. Since the 
MMPs are proteases, they are produced intra-cellularly as zymogens with a pro-domain 
that renders them catalytically inactive; following removal of the signal sequence, the 
pro-domain is at the amino terminal. All MMPs have a pro-domain and all but one have 
what is termed a “cysteine switch” in the pro-domain to maintain zymogen status 
(Nagase et al., 2006). Within the pro-domain the MMPs contain the highly conserved 
PRCGXPD cysteine switch amino acid sequence; the cysteine in the conserved sequence 
will coordinate with the zinc atom contained within the catalytic domain, which folds the 
pro-domain over top of the catalytic domain and prevents the zymogen from interacting 
with any substrates until the pro-domain has been removed (Nagase and Murphy, 2008). 
For 10 MMPs, removal of the pro-domain occurs intracellularly by a pro-protein 
convertase, most notably Furin, which cleaves the pro-domain from the rest of the 
zymogen at a conserved sequence of RXRXKR located at the junction between the 
catalytic and pro-domains (Yana et al., 2000; Nagase et al., 2006). The other 15 MMPs 
are activated extra-cellularly in cooperation with the MMPs activated intra-cellularly, 
which does not fully remove the pro-domain of the 15 MMPs, but rather begins the 
process by making a cleavage within the pro-domain that is finished auto-catalytically by 
the MMP being activated; this process has been well-characterized for MMP-2 
(Morgunova et al., 1999; Sternlicht and Werb, 2001; Nie and Pie, 2003; Morrison and 
Overall, 2006). The catalytic domain of the MMPs is the most highly conserved domain 
in the family and to be considered an MMP, family members must display catalytic 
domain amino acid sequence homology to MMP-1 (Murphy and Nagase, 2008). All 
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MMPs contain a conserved HEXXHXXGXXH sequence that sits at the center of the 
catalytic domain and is vital to the enzymes’ activity; it is the three Histidine residues 
that will coordinate the zinc atom at the active site with the assistance of, first, the 
cysteine residue in the cysteine switch of the pro-domain and, second, a water molecule 
once the enzyme has been activated (Nagase et al., 2006). All MMPs, with only three 
exceptions, contain a hemopexin-like domain at their carboxy terminal that is attached to 
the central catalytic domain through a flexible “hinge” region (Murphy and Nagase, 
2008). The hemopexin-like domain affects MMP substrate specificity, proteolytic 
activity, pro-MMP activation and MMP inhibition (Sternlicht and Werb, 2001; Wang et 
al., 2004). In addition to all the previous structural features, there are seven MMPs 
classed as membrane-type MMPs (MT-MMPs). Whereas the other 18 MMPs end with 
the hemopexin-like or catalytic domains at their carboxy terminals and are simply 
secreted outside of the cell, these MMPs have either a trans-membrane domain that 
integrates them into the plasma membranes of cells or are attached to the exterior of the 
cell’s plasma membrane through a glycosyl-phosphatidyl inositol (GPI) anchor that links 
the carboxy terminal of the MMP protein to the GPI group (Sohail et al., 2008). 
1.3.2 Classifications and Substrate Specificity                   
The MMPs were once classified into sub-groups according to their function and 
primary substrates, but are now usually referred to by their numeric order. MMP-1, -8 
and -13 are the collagenases and cleave collagen types I, II and III preferentially. MMP-2 
and -9 are the gelatinases and cleave a wide variety of ECM and basement membrane 
proteins including denatured collagen from which they derive their name. MMP-3, -10 
and -11 are stromelysins, which are similar to the collagenases, but can not cleave as 
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many substrates. MMP-12, -20 and -27 have not yet been grouped as stromelysins, but 
share all the same characteristics. The matrilysins (MMP-7 and -26) are also referred to 
as minimal domain MMPs as they contain only the conserved pro and catalytic domains 
and lack a hemopexin-like domain. In addition to ECM protein substrates, these MMPs 
can also activate pro-cytokines (Parks et al., 2004). The MT-MMPs are classed within 
themselves, but also in the larger family context. Thus MT1-MMP is MMP-14, MT2-
MMP is MMP-15, MT3-MMP is MMP-16 and MT5-MMP is MMP-24. These are the 
integral trans-membrane MT-MMPs while MT4-MMP (MMP-17) and MT6-MMP 
(MMP-25) are the GPI-anchored MT-MMPs (Murphy and Nagase, 2008). In addition to 
various sub-groups, the MMPs can be broadly classed into two large categories: the MT-
MMPs and the secreted MMPs.         
1.3.3 Tissue Inhibitors of Metalloproteinases
The endogenous regulators of MMP activity are the tissue inhibitor of 
metalloproteinases (TIMPs), which paradoxically are involved not only in the inhibition 
of MMPs, but also their extra-cellular activation. There are four TIMPs that collectively 
can inhibit the entire MMP family in a 1:1 TIMP to MMP ratio; the amino terminal 
domain of TIMPs binds to the catalytic domain of the MMP while the TIMP carboxy 
terminal domain binds to the MMP hemopexin-like domain (Flannery, 2006). The TIMP 
amino domain acts like the pro-domain of MMP zymogens in that a critical cysteine 
residue in the amino domain displaces the water molecule coordinating with the zinc 
atom at the catalytic center, which covers the MMP active site and prevents any further 
catalysis (Nagase et al., 2006). In addition to their inhibitory actions, TIMPs can be 
utilized for the activation of some secreted MMPs in cooperation with membrane-
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associated MMPs. By binding to the catalytic domain of a membrane-associated MMP 
with their amino domain and to the hemopexin-like domain of the secreted pro-MMP 
with their carboxy domain, the TIMPs hold the secreted pro-MMP in place while another 
nearby membrane-associated MMP activates it (Birkedal-Hansen et al., 1993; 
Morgunova et al., 1999; Van Den Steen et al., 2001; Bernardo and Fridman, 2003). In 
more recent years additional activities not related to the MMPs have been attached to the 
TIMPs. Mitogenic and anti-apoptotic properties have been described for TIMP-1 and -2 
while a pro-apoptotic role has been outlined for TIMP-3 in addition to inhibiting the 
vascular endothelial growth factor signaling pathway and angiogenesis by binding to the 
growth factor’s receptor (Murphy and Nagase, 2008).   
1.3.4 Roles in Disease States
1.3.4.1 Autoimmune
Autoimmune diseases are characterized by the cells of the immune system 
attacking self targets within the body instead of proper pathogenic targets. The arthritides 
are common autoimmune diseases and as enzymes that degrade the ECM, which is the 
target of degradation in the arthritides, the MMPs have a role in the progression of both 
osteoarthritis and rheumatoid arthritis. The cartilage of joints is composed primarily of a 
proteoglycan called aggrecan, which can be hydrated in association with other 
proteoglycans, and type II collagen (Poole, 1999). Rheumatoid arthritis is a systemic, 
chronic inflammation of joints typically found in elderly populations whereas 
osteoarthritis tends to develop in joints that have been injured or worn down and can 
develop in younger individuals. In both cases there is a cytokine signaling cascade that 
initiates ECM breakdown by up-regulating expression of ECM proteinases, which 
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releases growth factors and pro-cytokines that further stimulate synthesis and secretion of 
ECM proteinases like the MMPs (Burrage et al., 2006). The predominant MMPs 
involved in the progression of the arthritides are MMP-1, -3 and -13 with conflicting 
evidence regarding a role for MMP-9 (Burrage et al., 2006; Naito et al., 1999; Ram et al., 
2006). Over-expression of MMP-1, -3 and -13 occurs in synovial fibroblasts and cartilage 
cells within the joint due to cytokine stimulation, primarily IL-1 and TNF-α, which is 
produced by macrophages and the chondrocytes. The cytokine signal transduction 
pathway involves various kinases that will eventually up-regulate expression of MMP-1, 
-3, -13 and pro-TNF-α, which is activated outside of the cell and then acts in an autocrine 
and paracrine manner to further increase expression of itself and the three MMPs 
(Vincenti and Brinckerhoff, 2002; Nah et al., 2007). The targets of MMP-1, -3 and -13 in 
the arthritides are the ECM components aggrecan and type II collagen. All three MMPs 
cleave aggrecan at a specific site that removes a key domain and prevents aggrecan from 
binding hyaluronan anymore; this lack of binding decreases localized hydration (Takaishi 
et al., 2008). Type II collagen is the major collagen in joints and is efficiently cleaved, 
which leads to its denaturation at physiological temperature, by MMP-1 and -13 
(Takaishi et al., 2008). Though the initiation of osteoarthritis and rheumatoid arthritis is 
different, localized over-expression of MMP-1, -3 and -13 by fibroblasts and 
chondrocytes in the joints leads to a vicious cycle in which key ECM components are 
continually degraded until the joint is no more. 
Multiple sclerosis (MS) is another autoimmune disease in which there is emerging 
evidence to support a role for the MMPs. MS is a chronic disease characterized by a 
break down of the myelin protein sheath of nerves within the central nervous system. 
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There are two stages of MS: initial development and relapses, which occur since the body 
tries to re-myelinate damaged areas. Exactly how MS is initially triggered remains 
unclear, but the disease develops when T cells and macrophages of the immune system 
invade the central nervous system and begin degrading the myelin covering of nerves; 
this is a process that involves MMP-9 and, secondarily, MMP-2 as the immune system 
cells utilize these proteases to both gain access to the central nervous system and degrade 
myelin (Leppert et al., 1998; Sastre-Garriga et al., 2004). One study found expression of 
MMP-9 significantly increased in all patients with relapsing MS and in 57% of patients 
initially developing MS; they hypothesized that immune system cells infiltrating the 
central nervous system and causing the MS were the source of the increased MMP-9 
expression (Leppert et al., 1998). Further work found expression of MMP-9 and -2 and 
their endogenous regulators, TIMP-1 and -2 respectively, in MS patients was correlated 
with severity of the disease at the time; when patients were in a recovery phase, MMP 
expression was low and TIMP expression was higher, however when patients were in a 
relapse state, MMP expression was high and TIMP expression low (Liuzzi et al., 2002; 
Benešová et al., 2009). Treatment of MS with interferon-beta resulted in sustained 
increased expression of TIMP-1 and a positive response to treatment. Although there was 
no sustained decrease in MMP-9 and -2 levels, the increase in TIMP-1 levels could have 
been responsible for the positive response to treatment by blunting the effects of MMP-9 
and -2 (Comabella et al., 2009). Finally, polymorphisms within the promoters of MMP-9 
and -2 were believed to be linked to MS and indicate a genetic susceptibility, but analysis 
indicated only one of two MMP-2 polymorphisms was correlated with a higher risk of 
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MS in women while there was no such association with MMP-9 polymorphisms 
(Benešová et al., 2008).    
1.3.4.2 Cancer
Development of cancer is complex and can depend on tissue of origin, but two of 
the central characteristics of these diseases are the growth and metastasis of primary 
tumours. To facilitate growth and metastases, tumours heavily over-express some MMPs 
and many of the most common cancers are linked to MMP over-expression. 
Lung cancer is the most common cancer in North America. Two MMPs, MMP-2 
and -7, play a large role in the progression of lung cancer and tumours expressing these 
MMPs at higher levels indicates a poor prognosis (Liu et al., 2007; Liu et al., 2008; 
Leinonen et al., 2008). In lung cancer tumours MMP-7 expression is downstream of the 
Wnt/β-catenin pathway, which is hyper-active in lung cancer (Huang et al., 2008). Once 
active MMP-7 is released into the ECM of tumours it can locally enhance insulin-like 
growth factor signaling by cleaving insulin-like growth factor binding protein 3, which 
stimulates increased cell proliferation within the tumour (Miyamoto et al., 2004). Other 
MMP-7 substrates include type IV collagen and proteoglycans that comprise the bulk of 
the ECM, which enables MMP-7 to further aid increased cell proliferation within lung 
cancer tumours by removing ECM barriers to increased tumour growth (Ii et al., 2006). 
MMP-7 is also able to cleave the extra-cellular domain of E-Cadherin (Davies et al., 
2001), which causes cells to lose contact with one another and leads to a cellular 
phenotype more conducive to invasion and metastasis in cancer, although it is still 
unclear if it plays this role in lung cancer. MMP-2 is involved in growth and metastasis of 
lung cancers through angiogenesis facilitation, which is a key requirement for tumours to 
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grow larger, and suppression of apoptosis. MMP-2 expression in lung cancer is 
downstream of the PI3K signaling pathway (Saito et al., 2006), which is very commonly 
altered in many cancers so it is constitutively active. In a lung cancer cell line MMP-2 
expression knocked down with siRNA resulted in increased endothelial cell apoptosis 
and inhibited the formation of endothelial tubes, which are precursors to new blood 
vessels and essential for tumours to grow larger (Chetty et al., 2008). Knockdown of 
MMP-2 expression also stimulates apoptosis in lung cancer cells by preventing the 
cleavage of Fas ligands on the extra-cellular surface of the plasma membrane (Chetty et 
al., 2007).     
Colon cancer is a disease in which the gelatinases, MMP-2 and -9, figure 
prominently. Over-expression of MMP-2 and -9 in colon cancer tumours indicates a poor 
prognosis in the disease (Roeb et al., 2001; Hilska et al., 2007; Šundov et al., 2008). The 
gelatinases are acting as ECM-degrading enzymes and aid colon cancer progression by 
facilitating angiogenesis events and metastases. Expression and secretion of the 
gelatinases is downstream of the MAPK pathway and depends on protein-protein 
interactions between integrins and effectors of the MAPK pathway. Association of src 
tyrosine kinase, very commonly constitutively active in colon cancer and membrane-
localized, with the intra-cellular domain of α1-integrin results in recruitment and 
phosphorylation of downstream effector proteins that leads to an increase in both latent 
and active forms of MMP-2 and -9 in colon cancer cells (Van Slambrouck et al., 2007). 
Similarly, association of αvβ6-integrin and ERK1/2, a downstream effector of the MAPK 
pathway, at the plasma membrane results in the eventual up-regulation of MMP-2 and -9 
expression in colon cancer cells (Gu et al., 2002; Wang et al., 2008). The gelatinases are 
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key players in tumour angiogenesis (Itoh et al., 1998; Bergers et al., 2000; Chetty et al., 
2008), however direct evidence for an angiogenic role in colon cancer development has 
only been uncovered for MMP-9; in the ECM MMP-9 can cleave heparan sulphate, 
which releases vascular endothelial growth factor from ECM binding and facilitates 
angiogenesis in colon cancer tumours (Hawinkels et al., 2008). In addition to colon 
cancer tumour development, MMP-9 appears to play a specialized role in some 
metastases of colon cancer. In vitro and in vivo research indicated MMP-9 was critical in 
facilitating the spread of colon cancer cells to the lung by degrading ECM components 
that hindered the formation of locomotory apparatuses (Lubbe et al., 2006); however an 
examination of colon cancer metastasis to the liver indicated MMP-9 was not primarily 
responsible for these metastases, although it was still heavily involved in the progression 
of the colon cancer to an invasive phenotype (Illemann et al., 2006).      
       Breast cancer is the most common female-specific cancer in North America. 
Once again the gelatinases, MMP-2 and -9, as well as MMP-14, or MT1-MMP, are key 
players. Expression of MMP-2, -9 and -14 is positively correlated with aggressive and 
invasive breast cancer with lower levels of expression seen in earlier stage and less 
aggressive breast cancer (Figueira et al., 2009); Of the three MMPs, high MMP-14 
expression indicates a poor prognosis and low long-term survival (Têtu et al., 2006; Jiang 
et al., 2006). As in colon cancer, the expression, secretion and activation of the 
gelatinases in breast cancer is downstream of the MAPK signal transduction pathway and 
dependent on phosphorylated ERK1/2 (Lu et al., 2008; Sun et al., 2009). Expression of 
the gelatinases is associated with vascular endothelial growth factor and angiogenesis in 
breast cancer tumours (Kurizaki et al., 1998). A common treatment for breast cancer is 
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the anti-estrogen drug, tamoxifen, which paradoxically increases levels of active MMP-2 
and -9 in breast cancer tumours, but also increases levels of TIMP-1, -2 and endostatin, 
an inhibitor of angiogenesis (Nilsson et al., 2007). Endostatin is the product of 
proteolytically-cleaved type XVIII collagen, a component of the ECM basement 
membrane (Marneros and Olsen, 2005); it carries out its anti-angiogenic activities in 
endothelial cells by down-regulating the expression of genes involved in migration 
including the gelatinases, which are also involved in cleavage of type XVIII collagen and 
endostatin formation, but also by binding to the catalytic domain of active MMP-2 in the 
pericellular environment (Shichiri and Hirata, 2001; Bendrik et al., 2008; Lee et al., 
2002). The pro-angiogenic role for the gelatinases in breast cancer progression is 
tempered by their production of the anti-angiogenic peptide fragment endostatin, which 
doubles back and inhibits their expression and activity (Lee et al., 2002; Nilsson et al., 
2007; Lu et al., 2008; Bendrik et al., 2008). In addition to its pro-angiogenic role, MMP-2 
is involved in metastasis of breast cancer tumours through digestion of endothelial 
basement membrane components that would otherwise prevent the entry of cancer cells 
into blood vessels (Kargozaran et al., 2007). 
MMP-14 has dual roles in invasive breast cancer; first, it is a protease with 
substrates that include many key components of the ECM and basement membrane, 
which allows it to facilitate increased tumour growth and metastases and, second, it is an 
activator of pro-MMP-2 (Bernardo and Fridman, 2003), which is itself implicated in 
breast cancer progression. Expression of MMP-14 in breast cancer cells is downstream of 
β-catenin signaling and dependent on the improper cytosolic localization of a crucial tight 
junction protein called zonula occludens-1 (ZO-1), which allows un-phosphorylated β-
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catenin to accumulate and affect downstream gene transcription (Polette et al., 2005). 
Once expressed, MMP-14 is characteristic of invasive, metastatic breast cancers (Jiang et 
al., 2006) and is delivered in vesicles to the leading edge of tumours via the soluble N-
ethylmaleimide-sensitive factor attachment receptor (SNARE) protein, Vamp7, where it 
degrades its ECM substrates (Steffen et al., 2008).    
1.3.5 Roles in Normal Development
Much of the developmental work carried out by the MMPs enables cell 
proliferation and migration as the MMPs degrade ECM barriers. The MT-MMPs seem to 
play a more significant role in development than do the secreted MMPs; this is likely 
caused by their dual roles as proteases and activators of the secreted MMPs. One crucial 
developmental process that utilizes the MMPs is bone development. The majority of 
embryonic bone development occurs through endochondral ossification, where a cartilage 
template is laid down and subsequently replaced by a mineralized bone matrix; this 
matrix is then vascularized by capillaries and followed by bone-specific osteoclasts and 
osteoblasts, which proliferate and are responsible for establishing final bone development 
on the mineralized matrix as well as maintenance throughout life (Vu and Werb, 2000). 
The key MMPs for bone development are MMP-9, -13 and -14, or MT1-MMP.
MMP-9 is important for bone development by stimulating angiogenesis, through 
the capillaries invading the cartilage template, and apoptosis of the hypertrophic cartilage 
matrix, which allows a secondary wave of bone-specific cells to finalize development 
(Vu et al., 1998). MMP-9 expression is downstream of the Wnt/β-catenin signaling 
pathway in bone development as is that of vascular endothelial growth factor, a potent 
stimulator of angiogenesis (Tamamura et al., 2005). Vascular endothelial growth factor 
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trapped within the ECM is a target for active MMP-9 and once released it stimulates the 
recruitment of endothelial cells that will form capillaries and is a chemoattractant for 
osteoclasts. Passage of the endothelial and osteoclastic cells through the un-mineralized 
cartilage template is also mediated by the proteolytic capabilities of MMP-9 (Engsig et 
al., 2000). Apoptosis of the chondrocytes within the cartilage template is required 
concurrent with the migration of endothelial and osteoclastic cells in proper bone 
development. Resorbing chondrocytes highly express MMP-9, as do the invading 
endothelial and osteoclastic cells, and lack of MMP-9 results in decreased cartilage 
apoptosis and migration into the bone matrix (Takahara et al., 2004); the pro-apoptotic 
and pro-migration actions of MMP-9 can also be attributed to its cleavage of ECM 
downstream effectors that interact with additional ECM components (Ortega et al., 2005). 
The evidence to support a strong role for MMP-9 in bone development is strong and 
Mmp9-/- mice display developmental defects in embryonic bone development related to 
impaired apoptosis and angiogenesis, however these defects are eventually compensated 
for post-natally and Mmp9-/- mice are viable and normal about a month after birth (Vu et 
al., 1998). 
Much like MMP-9, the role of MMP-13 in bone development regards degradation 
of the ECM in the un-mineralized cartilage template; expression of MMP-13 is high in 
terminally-differentiating cartilage and active MMP-13 is required to initiate the 
establishment of the mineralized bone matrix in place of the cartilaginous template 
(D’Angelo, et al., 2000). Two main components of the cartilage ECM, type II collagen 
and the proteoglycan aggrecan, and type I collagen in bone are substrates for MMP-13 
and lack of MMP-13 expression in the cartilage template results in significantly higher 
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levels of surviving chondrocytes and reduced migration of bone-producing cells into the 
bone matrix (Stickens et al., 2004). Expression of MMP-13 is downstream of both the 
Wnt/β-catenin (Tamamura et al., 2005) and MAPK signaling pathways in the terminally-
differentiating chondrocytes (Ronzière et al., 2005). Expression of MMP-13 via the 
MAPK pathway is dependent on α1β1-integrins, which are extra-cellular receptors for 
both type I and II collagen (Ronzière et al., 2005). Research indicates there is a switch 
from type II collagen to type I collagen in the cartilage template just prior to degradation 
that could signal to the α1β1-integrins and, subsequently, MAPK pathway to increase 
MMP-13 expression (Ronzière et al., 2005). Mice that are Mmp13-/- display a phenotype 
similar to Mmp9-/- mice; there is decreased chondrocyte apoptosis, vascularization and 
bone-specific cell migration, but post-natally these defects are eventually compensated 
for and Mmp13-/- mice are largely normal (Inada et al., 2004), however as adults they do 
have problems with repairing bone fractures and breaks (Behonick et al., 2007).
The most important MMP contributor to bone development is MMP-14 or MT1-
MMP. Not only is it an activator of certain secreted MMPs, but it is also a peri-cellular 
protease with ECM substrates. Like MMP-9 and -13, MMP-14 facilitates vascularization 
of the cartilage template, which leads to mineralization and bone development, as well as 
delayed apoptosis of the terminally-differentiated chondrocytes and ossification (Zhou et 
al., 2000). Expression of MMP-14 in pre-osteoblasts is induced by the ECM components 
type I collagen and fibronectin binding to α2β1-integrin or α4/α5β1-integrin dimers 
respectively, which activate the MAPK signaling pathway; up-regulation of MMP-14 
expression in the pre-osteoblasts results in mineralization of the cartilage template and 
ossification (Manduca et al., 2009). MMP-14 is also indispensable to immediate post-
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natal bone development in which it mediates a type of non-endochondral bone 
development that resorbs and replaces the cartilage template with bone, but skips the 
mineralization of the cartilage step (Holmbeck et al., 2003). Unlike Mmp9-/- and Mmp13-/- 
mice, Mmp14-/- mice have profound skeletal defects that include skull malformations, 
decreased bone density after birth, osteoarthritis, disrupted vascularization of the cartilage 
template in future bone, delayed hypertrophic chondrocyte apoptosis and delayed 
ossification of the mineralized cartilage template by reduced osteoclast and osteoblast 
activity (Holmbeck et al., 1999). In addition to the bone defects, the Mmp14-/- mice never 
sexually mature and most die between 50 and 90 days (Holmbeck et al., 1999). Despite a 
strong role in bone development for MMP-9 and -13, their mouse knockout models were 
able to eventually compensate for the loss of those two MMPs; the loss of MMP-14 was 
obviously unable to be developmentally compensated for indicating a more important and 
non-redundant role for MMP-14 in bone development. The importance of the MMPs in 
bone development has been well characterized, however the role they play in SP 
development, which also involves ossification, remains unclear.                       
1.4 Matrix Metalloproteinases and Palatogenesis
Little is currently known about what role the MMPs play in SP development. An 
association between the MMPs and craniofacial morphogenesis was first noted in 1997; 
expression of MMP-2 was detailed throughout the developing mouse face (Iamaroon et 
al., 1997) while a functional role in mandibular, tongue and facial cartilage development 
was outlined for the MMPs as a family (Chin and Werb, 1997). Expression of the MMPs 
and TIMPs in SP development was first outlined in 1999 and then refined in 2000; MMP-
2, -3, -7, -9, -13, TIMP-1 and -2 expression was found to be temporally regulated in the 
38
developing mouse SP (Morris-Wiman et al., 1999) while further investigation determined 
expression of MMP-2, -3, -9, -13, TIMP-1, -2 and -3 was not only temporally regulated, 
but also spatially within the SP according to local concentration of their primary 
substrates (Morris-Wiman et al., 2000). A functional role for the MMP family in SP 
development was described in 2001 and confirmed in 2002; treatment of in vitro palatal 
cultures with a chemical inhibitor of the MMPs blocked fusion of the palate shelves and 
resulted in persistence of the MEE in contacted areas (Blavier et al., 2001; Brown et al., 
2002). Early hypotheses, based on expression of the MMPs in the SP, focused on MMP-
2, -3 and -9 as the MMPs with functional roles in SP development (Morris-Wiman et al., 
2000; Brown et al., 2002), however Mmp2-/-, Mmp3-/- and Mmp9-/- mouse models were 
fertile, viable and, most importantly, did not display a CP phenotype (Itoh et al., 1997; 
Shapiro, 1997; Vu et al., 1998). Which of the MMPs has a functional role in SP 
development remained unknown for years as no further research was done in the area 
since Blavier et al., 2001 and Brown et al., 2002, however recent work has implicated the 
MT-MMPs as being the primary MMPs in SP development. Mice with a double knockout 
of MT1- (MMP-14) and MT3-MMP (MMP-16) have a complete CP (Shi et al., 2008), 
but mice with a single knockout of either MT1- or MT3-MMP do not, although they do 
have other severe developmental defects (Shi et al., 2008; Holmbeck et al., 1999). These 
results demonstrate crucial, non-redundant functions for the MT-MMPs, however in SP 
development it appears MT1-MMP is able to compensate for MT3-MMP when it is 
knocked out so a role for a single MMP still remains unclear in SP development, 
although a new candidate is MT6-MMP or MMP-25. 
1.5 Matrix Metalloproteinase-25
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MMP-25 was the sixth MT-MMP cloned and the second GPI-anchored MT-MMP 
(Kojima et al., 2000), which means it is attached to the exterior of the cellular plasma 
membrane rather than embedded in it. MMP-25 contains the same conserved domains of 
the other MMPs: amino terminal signal sequence, pro-domain with RXRXKR activation 
sequence, catalytic domain, hinge region, hemopexin-like domain and a GPI-anchoring 
region at the carboxy terminal (Pei, 1999). 
Mmp-25 was first cloned in 1999 from human leukocytes and was hypothesized to 
facilitate leukocyte invasion to sites of injury through proteolytic degradation of ECM 
and basement membrane components (Pei, 1999). Further investigation into leukocytes 
determined Mmp-25 expression was restricted to the neutrophil sub-population, 
predominantly found in cytosolic granules and vesicles and MMP-25 was deployed by 
neutrophils when stimulated by cytokines (Kang et al., 2001); a more systemic look at 
Mmp-25 expression found mRNA in all organs examined with highest expression in the 
heart and lungs (Nuttall et al., 2004). 
ECM and basement membrane substrates of MMP-25 include gelatin, type IV 
collagen, fibrinogen, fibrin, fibronectin, chondroitin sulfide and dermatin sulfide (Kang et 
al., 2001; English et al., 2001) and its catalytic activities were inhibited strongest by 
TIMP-1, but also effectively by TIMP-2 and -3 (English et al., 2001); MMP-25 is also 
significantly inhibited via its hemopexin-like domain by clusterin, a protein that inhibits 
the other GPI-anchored MT-MMP, MMP-17, but does not do so for any other MMPs 
examined (Matsuda et al., 2003). Additional targets for active, membrane-localized 
MMP-25 could include activation of pro-MMP-2, however evidence for this is 
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conflicting (Kojima et al., 2000; Velasco et al., 2000; Nie and Pie, 2003; Sun et al., 
2007).     
Like other MMPs, Mmp-25 is over-expressed in certain cancers. Expression of 
Mmp-25 is very low in the brain normally, but significantly up-regulated in astrocytoma 
and glioblastoma brain tumours, likely indicating a proteolytic role in the development of 
these tumours in vivo (Velasco et al., 2000). Similarly, expression of Mmp-25 is absent in 
the healthy colon, but is significantly increased in in vivo colon cancer and transfection of 
colon cancer cell lines with vectors expressing Mmp-25 resulted in those cell lines 
acquiring an aggressive, invasive phenotype relative to controls (Sun et al., 2007). MMP-
25 over-expression has also been linked to urothelial and prostate cancers (Sohail et al., 
2008).
No role for MMP-25 in embryonic development has ever been described, 
however genomic scans of the DNA of human CP patients revealed consistent 
appearance of markers at a locus just upstream of what turned out to be the Mmp-25 gene 
(Blanton et al., 2004). These researchers determined there was a significant enough 
association between Mmp-25 and CP to justify a molecular investigation into the role of 
MMP-25 and SP development, which was the basis for this current study.
1.6 Implications for Research
CP is one of the most common birth defects today. As such its cumulative costs are large, 
both financially and socially. Of course direct financial estimates do not take into account 
peripheral costs such as traveling, accommodations or time off work during hospital 
stays. Over an individual’s lifetime all of these costs will accumulate. Social costs can 
also accumulate. Because CP is better hidden from the world than CL/P, most studies 
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examining the psychological and social consequences of orofacial clefting have focused 
on CL/P. Yet with so many visits to medical specialists, including speech pathologists, 
even a young child with CP can not fail to understand they are different and might feel 
less attractive to the world because of their multiple surgeries and/or speech problems. So 
it is probable that patients with CP also suffer from psychological and social isolation, 
though it may not be as severe as those with CL/P, who are more noticeably dissimilar. 
Research into Mmp-25 in the SP will help researchers understand the formation of 
the SP better and enhance knowledge about the MMP family during tissue remodeling 
events. Combined with research into environmental contributing factors, this information 
will make combating CP easier as its origins will gradually become better understood, 
making available new treatment strategies that can be used in the prevention and therapy 
of CP in children.    
 
2. Materials and Methods
2.1 Primer Design and Semi-Quantitative and Quantitative PCR 
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All mice were handled and research carried out in accordance with the University 
Committee on Animal Care and Supply. Total RNA isolations were done on embryonic 
CD-1 mouse SP tissue using the RNeasy® Mini Kit according to manufacturer’s protocol 
(Qiagen, Mississauga, ON). RNA isolations were done on SP tissue corresponding to 
days E12 to E15. Reverse transcriptase PCR (RT-PCR) was carried out on total RNA 
isolations using the SuperScript™ RNase H-Reverse Transcriptase according to 
manufacturer’s recommendations to generate embryonic SP complementary DNA 
(cDNA; Invitrogen, Carlsbad, CA). 
Semi-Quantitative PCR primers were designed to recognize the 3΄ end of mouse 
Mmp-25 mRNA transcripts. The primers amplified a deoxynucleotide fragment of 295 
base pairs (bp) from an embryonic murine SP cDNA pool if Mmp-25 cDNA is present. 
Due to homology with other murine mRNAs, the Mmp-25 mRNA sequence was aligned 
with these mRNAs and examined for regions of low homology using the online multiple 
sequence alignment software, ClustalW (Appendix A). The primers were then 
constructed and chosen using Primer3 (v.0.3.0) and NetPrimer software available online 
(Appendix A). Finally, primer sets were analyzed using the online nucleotide basic local 
alignment search tool (BLASTn) to ensure that only Mmp-25 cDNA would be amplified 
during subsequent PCR (Appendix A). Final Semi-Quantitative PCR primer sets are 
displayed in Table 1.  
Semi-Quantitative PCR was carried out using the EconoTaq™ DNA polymerase 
and 1x reaction buffer (10 mM Tris-HCl, 50 mM KCl, 0.1% Triton X-100, 1.5 mM 
Table 1: List of Semi-Quantitative PCR primer sets designed to amplify an 
oligodeoxynucleotide fragment using Mmp-25 cDNA as a template.
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MgCl2) according to manufacturer’s specifications (Lucigen, Middleton, WI). All Semi-
Quantitative PCR used a final volume of 50 μl unless otherwise noted and was done on a 
MJ Research PTC-100 Thermal Cycler (Bio-Rad, Mississauga, ON). To amplify the 295 
bp fragment from Mmp-25 cDNA, cycling conditions were as follows: 1 cycle at 95oC for 
3 min followed by 30 cycles at 94oC for 1 min, 55oC for 1 min, 72oC for 2 min completed 
by 1 cycle at 72oC for 8 min. Semi-Quantitative PCR products were visualized using 1% 
agarose gel electrophoresis (100 ml) and 70 nanograms of ethidium bromide. The size of 
Semi-Quantitative PCR products was compared relative to the Ready-Load™ 1 Kb DNA 
Ladder (Invitrogen).   
qRT-PCR was carried out using the E12 to E15 SP cDNA described above, an 
Mmp-25-specific TaqMan® Gene Expression Assay according to manufacturer’s protocol 
(Applied Biosystems, Foster City, CA) and a 7300 Real Time PCR System (Applied 
Biosystems). qRT-PCR was analyzed using the Sequence Detection Software (v. 1.4) 
supplied with the 7300 Real Time PCR System (Applied Biosystems). Relative 
quantitation (RQ) values for the SP were obtained in comparison to a β-actin control and 
standardized to an E15 test run. The β-actin control was validated on a standard curve to 
ensure measurements would only take place during the exponential phase and did not 
vary between runs. Statistical analysis on the RQ values developed by the Sequence 
Detection Software (v. 1.4) was carried out using GraphPad Prism for Windows (v. 5.01; 
GraphPad Software Inc., La Jolla, CA).    
2.2 In Vitro Embryonic Mouse Palate Cultures
Name of PCR Primer 5’ -> 3’ Primer Sequence
Mmp25a (Sense) CGAAAACGACATCCAAAACC
Mmp25b (Antisense) CCCTAACAGAAAGCAGACTCA
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Pregnant CD-1 mice (E13) were killed by cervical dislocation after anaesthesia 
with Halothane® (MTC Pharmaceuticals, Cambridge, ON) and the embryos were 
aseptically removed in Hanks’ Balanced Salts solution (Sigma-Aldrich, Oakville, ON). 
The SPs were aseptically dissected and palate shelf cultures set up as previously 
described (Shiomi et al., 2006; Nakajima et al., 2007) with two modifications: the 
addition of 1M HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) to a final 
concentration of 20mM and addition of a penicillin-streptomycin antibiotic solution to a 
final concentration of 0.1% (Sigma-Aldrich). Briefly, the E13.0 palate shelves were 
excised and arranged in pairs with their medial edges in contact and in proper anterior-
posterior orientation on Nucleopore Polycarbonate Track-Etch filters (8.0 µm pore; 
Whatman, Inc., Newton, MA). Up to three filters were floated in a 35mm tissue culture 
dish containing 1.4 mL of BGJb medium (Invitrogen), supplemented as detailed above, 
and incubated with 5% CO2 at 37oC for 72 h. Following 72 hours incubation, 10 palatal 
cultures from each group (wild-type, scrambled siRNA control, Mmp-25 siRNA) were 
immersed in freshly-prepared 4% paraformaldehyde for approximately 2 h then placed in 
30% sucrose. The preserved palate cultures were embedded in Tissue-Tek® O.C.T. 
Compound (Sakura Finetek U.S.A., Inc., Torrance, CA), frozen and serial sections (8 
µm) prepared. Serial sections were examined by myself in a non-blinded fashion and 
scored and the cumulative scores were averaged to obtain a mean fusion score (MFS) as 
previously described (Figure 6; Yu et al., 2008; Kang and Svoboda, 2002). The Kruskal-
Wallis non-parametric statistical test was performed on the MFSs of the groups to 
determine significance where significance is indicated by p < 0.05. After scoring, palate 
45
Figure 6: Standards used to obtain the mean fusion scores for the in vitro palatal cultures. 
Reprinted with permission from Yu et al., 2008.
sections were stained with hematoxylin and eosin (H&E) using the following modified 
protocol: 3 min. with hematoxylin followed by two changes of tap water, one change of 
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acid alcohol (0.5% hydrochloric acid in 95% ethanol), two changes of tap water, one 
change of distilled water, 1 min. with eosin, one change of 95% ethanol and mounting in 
50% glycerol. The remaining palate cultures were pooled for either RNA or protein 
isolations as detailed in 2.1 and 2.3 respectively.    
2.3 Western Blot Analysis with an MMP-25 Antibody
 All mice were handled and research carried out in accordance with the University 
Committee on Animal Care and Supply. Embryos from CD-1 mice were aseptically 
removed at stages E12 through E15 and placed in 1x phosphate-buffered saline (PBS). 
Embryos from each stage of SP development (ie: E12 to E15) had their SPs dissected out 
and preserved at -20oC in 1.5 ml eppendorf tubes for protein isolations, sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and Western blot analyses. The 
lungs, kidneys, liver, heart, spleen and brain were dissected from the adult female CD-1 
mouse, following removal of the embryos, to use as MMP-25 positive control organs 
during Western blot analysis (Nuttall et al., 2004; Bernal et al., 2005). To isolate proteins, 
thawed tissue was homogenized in 150 μl of modified radioimmunoprecipitation assay 
(RIPA) buffer (5 mM ethylenediaminetetraacetic acid (EDTA), 10 mM TRIS pH 8.0, 
0.1% sodium deoxycholate, 0.01% SDS, 1% Triton X-100, 150 mM sodium chloride, 1 
μg/ml leupeptin, 1 μg/ml aprotinin, 1 μg/ml pepstatin) using a mechanical homogenizer at 
4oC. Homogenized samples were centrifuged at 4oC and 11,000 revolutions per minute 
(RPM) for 15 min. The supernatant was transferred to a new 1.5 ml eppendorf tube and 
protein concentration was quantified using the DC Protein Assay kit (Bio-Rad). To 
prepare for SDS-PAGE, 2x SDS gel-loading buffer (100 mM TRIS pH 6.8, 4.0% SDS, 
0.2% bromophenol blue, 20.0% glycerol, 200 mM β-mercaptoethanol) was added to each 
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sample to give a final 1x concentration (Sambrook and Russell, 2001a). Samples were 
then boiled at 100oC for 10 min to denature proteins and could be stored at -20oC until 
future SDS-PAGE or used immediately.
SDS-PAGE gel preparation and SDS-PAGE was carried out according to 
established protocol (Sambrook and Russell, 2001b) with 1.5 mm thick stacking gels 
containing 4% polyacrylamide and 1.5 mm thick separating gels 10% polyacrylamide. 
From 10 µg to 25 µg total protein was loaded onto the polyacrylamide gels in addition to 
10 μl of the Kaleidoscope™ Precision Plus Protein™ Standard (Bio-Rad). SDS-PAGE was 
run at room temperature for approximately 1.5 h at 100 volts. Following SDS-PAGE, 
gels were either stained using 0.05% Coomassie Brilliant Blue or utilized in a Western 
blot transfer. Polyacrylamide gels were stained in 0.05% Coomassie Brilliant Blue 
according to established protocol (Sambrook and Russell, 2001c). 
For Western blot analysis, a Novex Mini-Cell electrophoresis tank containing an 
XCell II™ blot module was utilized in the transfer (Invitrogen). Proteins separated by 
SDS-PAGE were transferred to a PolyScreen® polyvinylidene fluoride (PVDF) transfer 
membrane (PerkinElmer, Waltham, MA). The XCell II™ blot module was filled, from 
cathode to anode, as follows: two blotting pads, filter paper, SDS-PAGE gel, PVDF 
transfer membrane, filter paper and two more blotting pads. Blotting pads and filter paper 
were soaked in 1x transfer buffer (24 mM Tris base, 192 mM glycine, 20% methanol) 
prior to assembly in the blot module. The PVDF transfer membrane was soaked in 100% 
methanol for 30 sec, rinsed twice in deionized water and soaked in 1x transfer buffer for 
at least 5 min prior to assembly in the blot module. Transfer of protein on to a PVDF 
membrane ran for approximately 2 h at 30 volts. The inner compartment of the blot 
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module was filled with 1x transfer buffer while the outer reservoir contained 650 ml of 
deionized water. Following the transfer, the PVDF transfer membrane was blocked at 4oC 
in 200 ml of 3% skim milk overnight on an Orbitron Rotator II (Boekel Industries Inc., 
Feasterville, PA).  
Subsequent to blocking the PVDF transfer membrane, Western blot analysis was 
performed. Following removal of the transfer membrane from the blocking solution, no 
washing steps occurred. The transfer membrane was rotated using a model 2000 Micro 
Hybridization Incubator (SciGene Corporation, Sunnyvale, CA) at room temperature 
with 3 ml of 3% skim milk containing the primary antibody in a 15 ml BD Falcon™ 
conical tube (BD Biosciences, Canaan, CT) for approximately 1.5 h. Primary antibody 
titres varied depending on the protein being probed and antibody being used. To assess 
MMP-25 levels, an anti-MMP-25 rabbit polyclonal antibody with an amino terminal 
epitope was utilized (1:2000; Santa Cruz Biotechnology Inc., Santa Cruz, CA). As a 
loading control, transfer membranes were probed with an anti-β-actin (1:1000; Santa 
Cruz Biotechnology Inc.) or anti-glyceraldehyde-3-phosphate dehydrogenase primary 
antibody (GAPDH; 1:20,000; Sigma-Aldrich). After incubation with the primary 
antibody solution, the transfer membrane was washed three times with 0.08% Tween-20 
(Polyoxyethylene-Sorbitan Monolaurate) in 1x PBS for 15 min. each. Following the wash 
steps, the transfer membrane was rotated at room temperature for 1.5 h with 3 ml of 3% 
skim milk containing a goat anti-rabbit IgG horseradish peroxidase-conjugated secondary 
antibody (1:2500; Bio-Rad) as the primary antibody was. After incubation with the 
secondary antibody, the transfer membrane was again washed three times for 15 min. 
each with 0.08% Tween 20 in 1x PBS. Subsequent to this, the transfer membrane was 
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soaked for 30 seconds in 2 ml of a 1:1 mixture of enhanced luminol reagent and oxidizing 
reagent from the Western Lightning™ Chemiluminescence Reagent Plus kit 
(PerkinElmer). After contact with the chemiluminescent reagent, the transfer membrane 
was lightly blotted on a piece of filter paper, enclosed in plastic wrap and secured with 
adhesive tape into one corner of an X-Omatic® cassette (Kodak, Toronto, ON). In a dark 
room, the transfer membrane was exposed to X-Omat™ Blue XB-1 X-ray film (Kodak) 
for various time periods to best enhance specific binding bands and minimize background 
non-specific binding. Following exposure to the chemiluminescent transfer membrane, 
the X-ray film was developed at 32oC in an Optimax® X-ray film developer (Protec®, 
Oberstenfeld, Germany). 
2.4 IHC with an MMP-25 Antibody
Embryos from CD-1 mice were aseptically removed at stages E12 through E15 
and placed in 1x PBS. Heads from each stage were removed by cutting through the neck 
with micro-dissecting scissors to include the mandible and placed in freshly-prepared 4% 
paraformaldehyde at 4oC. E12 heads were maintained in 4% paraformaldehyde at 4oC for 
approximately 16 h; E13 heads for 18-20 h; E14 heads for 24 h and E15 heads for 24 h. 
Following preservation in 4% paraformaldehyde, the heads were placed in 30% sucrose 
at 4oC and could be maintained for several weeks by changing the 30% sucrose every 
week. Embryonic heads were embedded in Tissue-Tek® O.C.T. Compound (Sakura 
Finetek U.S.A., Inc.), wrapped in tinfoil to prevent drying and frozen overnight at -20oC. 
Coronal sections were cut (8 μm) and placed on glass microscope cover-slips covered in 
0.5% gelatin (Sigma-Aldrich). IHC with an primary anti-MMP-25 antibody (1:50; Santa 
Cruz Biotechnology Inc.) was carried out as follows: two washes in 1x PBS for 30 min 
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each followed by a 20 sec exposure to pepsin digest-all solution (Zymed, San Francisco, 
CA), which was washed off by immersion in the 1x PBS for approximately three more 
minutes; blocking in blocking solution (3% skim milk, 0.1% Triton X-100 in 1x PBS) at 
room temperature for approximately 1.5 h; incubation with 100 μl of the primary 
antibody, made up in 1x PBS, for 2 h at room temperature followed by overnight at 4oC; 
two washes in 1x PBS for approximately 5 min each; incubation with 100 μl of the Alexa 
Fluor® 594 goat anti-rabbit IgG secondary antibody (1:400; Molecular Probes, Eugene, 
OR), made up in 1x PBS, for approximately 2 h at room temperature in the dark; 30 μl of 
Hoechst nuclear stain for 15 min at room temperature in the dark; two washes in 1x PBS 
for approximately 5 min each; mounting onto glass microscope slides using ProLong® 
Gold antifade reagent (Invitrogen). IHC was evaluated by observing sections on an 
Olympus BX40 fluorescent microscope (Olympus America Inc., Center Valley, PA) at an 
emission wavelength of 613 nanometers. Images were taken using Image-Pro Plus (v. 
6.2; MediaCybernetics, Inc., Bethesday, MD). Determination of non-specific staining 
was assessed by substituting 100 μl of 1x PBS in lieu of 100 μl of the primary antibody 
solution. All preceding and subsequent steps were carried out as described above.       
2.5 Mmp-25 Gene Knockdown using Mmp-25 siRNA
A role for Mmp-25 during SP development was determined using Mmp-25-
specific siRNA to degrade Mmp-25 mRNA transcripts and knockdown gene expression. 
Mmp-25-specific siRNA was added to the in vitro palate cultures described above in 2.2 
at a final concentration of 500 nanomolar (nM; Shiomi et al., 2006). Gene knockdown 
cultures and analysis was carried out as previously mentioned in 2.2. Stealth™ RNAi 
Mmp-25 siRNA (Invitrogen) and  TransIT –TKO® transfection reagent (0.2%; Mirus Bio, 
51
Madison, WI) were utilized. To assess non-specific siRNA effects on the in vitro palate 
cultures Stealth™ RNAi Negative Universal Control siRNA (Invitrogen) was added to 
some control cultures at a final concentration of 500 nM to match the Mmp-25 siRNA.   
2.6 Characterization of Mmp-25 Gene Regulation
To investigate the regulation of Mmp-25, a promoter analysis was completed 
using available online software such as the Eukaryotic Promoter Database (EPD), the 
Homeodomain Resource and the Transcriptional Regulatory Element Database (TRED) 
(Appendix A). The DNA-binding sequences of common transcription factors were 
retrieved using the TRED and Homeodomain Resource and the Mmp-25 promoter 
sequence from -1000 to +100 base pairs relative to the transcription start site (TSS) was 
retrieved from the EPD. The Mmp-25 proximal promoter was examined by entering the 
consensus DNA-binding sequences of various transcription factors into the EPD. This 
examination of indicated Mmp-25 could be regulated by Hoxa2 and TGFβ3, through its 
intracellular mediators Smad2/3 and Smad4. 
To determine if the transcription factor, Hoxa2, is involved in the transcriptional 
regulation of Mmp-25, qRT-PCR was carried out on cDNA from wild-type and Hoxa2-/- 
E12.5 to E15.5 SPs according to manufacturer’s protocol (Applied Biosystems) as 
described above. Statistical analysis of the RQ values obtained from qRT-PCR was 
carried out using Student’s t-test (p < 0.05) on GraphPad Prism for Windows (v. 5.01; 
GraphPad Software Inc.). 
Mmp-25 promoter analysis indicated Mmp-25 could be regulated by the growth 
factor, TGFβ3. Since TGFβ3 is a well-characterized molecule that regulates many 
developmentally-important genes, this growth factor could be the chief regulator of 
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Mmp-25 expression and is one of my research hypotheses. To assess whether TGFβ3 
affects Mmp-25 transcription, a TGFβ3-neutralizing antibody (R&D Systems, 
Minneapolis, MN) was added to the in vitro SP cultures described above at final 
concentrations of 5 µg/ml, 10 µg/ml and 25 µg/ml, thereby eliminating this secreted 
growth factor from the cultures, with one alteration: SP cultures were incubated for 24 h, 
not 72 h (Yu et al., 2008). Following completion of organ cultures, qRT-PCR and 
Western blots were done to determine the effect of TGFβ3 on Mmp-25 mRNA and 
protein levels respectively. To ensure an alteration in Mmp-25 expression could be 
attributed to a drop in TGFβ3 levels, western blot analysis was carried out on the same 
PVDF membrane as the MMP-25 blot using an anti-phospho-Smad1 antibody (Cell 
Signaling Technology, Danvers, MA; 1:500).
2.7 Statistical Analysis
All statistical analysis performed on qRT-PCR data groups was either Student’s t-
test with P < 0.05 or one-way analysis of variance (ANOVA) with P < 0.05 also 
indicating significance. Statistical analysis of the in vitro palatal culture MFSs was 
carried out using the non-parametric Kruskal-Wallis test with P < 0.05 indicating 
significance. A non-parametric test was carried out on the palatal cultures MFSs as 
scoring did not follow a normal distribution due to rankings (Figure 6). 
 
3. Results
3.1 Primer Design and Semi-Quantitative and Quantitative PCR
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Semi-Quantitative PCR primers were designed to amplify a 295 bp 
deoxynucleotide fragment using the 3΄ end of Mmp-25 cDNA as a template. Semi-
Quantitative PCR analysis of Mmp-25 cDNA using the Mmp25a and Mmp25b primers 
(Table 1) indicates that Mmp-25 mRNA is expressed at all stages of SP development, 
from E12 through E15 (Figure 7). Semi-Quantitative PCR does not properly show if 
Mmp-25 mRNA expression during SP development is constitutive or if there might be 
up- and down-regulation of Mmp-25 so qRT-PCR was done.   
To determine if Mmp-25 mRNA expression is constitutive or variable during SP 
development, qRT-PCR was carried out. Further examination using qRT-PCR indicates 
there is a significant down-regulation in Mmp-25 mRNA expression at E15.5 relative to 
E13.5 using one-way ANOVA (P < 0.05; Figure 8A). As an ECM-degrading enzyme, a 
role for MMP-25 in SP development could be breaking down ECM barriers during palate 
shelf growth. By E15.5 the palate shelves have fused and the MES is largely degraded 
thus maintaining increased expression of Mmp-25 is no longer necessary.       
3.2 Western Blot Analysis with an MMP-25 Antibody
Total protein from E12.5 to E15.5 SP protein isolations was separated via SDS-
PAGE and probed for MMP-25 protein presence. Western blot analysis indicates MMP-
25 exists at approximately 55 kilodaltons (kDa) in the mouse SP throughout 
palatogenesis (Figure 8B). This is in agreement with previous reports of MMP-25 at 57 
kDa in white blood cells and a colon cancer cell line (Kang et al., 2001; Kuula et al., 
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Figure 7: Polymerase chain reaction (PCR) and a 1% agarose gel confirm that Mmp-25 
messenger RNA (mRNA) is expressed in the mouse secondary palate (SP) from 
embryonic (E) days 12.5 through 15.5. Total RNA isolations were performed on mouse 
SP tissue from E12.5 to E15.5. Isolated RNA was reverse-transcribed into 
complementary DNA (cDNA). PCR was performed using the E12.5 through E15.5 
cDNA as template. Expected fragment size was 295 base pairs if Mmp-25 mRNA had 
been present and reverse-transcribed. Lane 1 represents 0.5 μg of Ready-Load™ 1 Kb 
DNA Ladder used to approximate the sizes of DNA bands on the gel (Invitrogen). Lane 2 
represents E12.5. Lane 3 represents E13.5. Lane 4 represents E14.5. Lane 5  represents 
E15.5.  
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Figure 8: Mmp-25 mRNA and protein expression. (A) quantitative real-time PCR 
displays significantly higher Mmp-25 mRNA expression at embryonic day (E) 13.5 
relative to E15.5 using one-way ANOVA (P < 0.05). N = 4 for each stage with four 
replicates within each N; error bars indicate standard error of the mean. (B) Western blot 
analysis shows MMP-25 protein levels parallel mRNA levels with higher protein 
expression at E12.5 and 13.5 when compared to E15.5. Approximately 20 μg of total 
protein was separated using 10% sodium dodecyl sulfate poly-acrylamide gel 
electrophoresis, transferred to a polyvinylidene fluoride membrane and probed with an 
anti-MMP-25 antibody (Santa Cruz; 1:1000). An anti-GAPDH antibody (Sigma-Aldrich; 
1:15,000) was used to assess loading equivalency.
2008; Sun et al., 2007). Western blots using an anti-GAPDH antibody (Sigma-Aldrich) 
indicate equivalent amounts of protein were loaded for MMP-25 Western blots.    
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3.3 Immunohistochemistry with an MMP-25 Antibody
IHC was carried out on 8 μm-thick coronal sections made from E12.5 to E15.5 
mouse heads as detailed above. At all stages examined, MMP-25 expression is strong in 
the epithelium of the palate shelves and degrading MEE of later stages with secondary 
expression in the mesenchyme immediately adjacent to epithelium at E12.5 and E13.5 
before becoming more dispersed in the mesenchyme at E14.5 and E15.5 (Figure 9). 
Expression of MMP-25 in the epithelium and mesenchyme at E12.5 and E13.5 appears to 
be strongest in the apical, or tip, area of the growing palate shelves; at E14.5 expression 
in the palate shelf epithelium seems strongest in the MEE and mesenchyme expression is 
less restricted to the apical portion of the palate shelves; at E15.5, as the MES is 
degrading, epithelial expression of MMP-25 is strongest in the oral epithelium with 
mesenchyme expression becoming stronger and more scattered throughout the SP. 
 3.4 Mmp-25 Gene Knockdown using Mmp-25 siRNA
 To obtain a more objective measure of the Mmp-25 siRNA effects, serial sections 
(8 μm) of preserved and frozen palatal cultures were generated. Every 8th section was 
examined by light microscopy and up to 15 sections were examined in total. Each section 
was given a score based on the completeness of fusion and quantity of remaining 
epithelium where 1 indicates no contact between the palate shelves and 5 indicates 
complete fusion (Kang and Svoboda, 2002). For each palatal culture thus examined the 
scores were combined and averaged to obtain a mean fusion score (MFS) and these MFSs 
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Figure 9:  Immunohistochemical analysis of mouse secondary palate coronal sections 
from embryonic day (E) 12.5 to 15.5 with an MMP-25 antibody (Santa Cruz; 1:50). (A-
D) Hoechst nuclear staining; scale bar = 10 μm. (E-H) Immunofluoresence shows MMP-
25 is strongly expressed in the epithelium of the palate shelves throughout development. 
Expression in the mesenchyme is secondary to the epithelium and restricted to the apical 
area of the palate shelves at E12.5 and 13.5 before becoming more widespread at E14.5 
and 15.5. (I-L) Increased magnification view of the boxes in E-H. Arrowheads indicate 
areas of high MMP-25 expression; scale bar = 5 μm 
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could themselves be averaged for an entire group. The results of the in vitro palatal 
cultures treated with 500 nM Mmp-25-specific siRNA are summarized in Table 2. 
Table 2: Summary of results for in vitro palate cultures treated with Mmp-25 siRNA
Condition Total MFS
Wild-type 10 4.14
Scrambled control siRNA 10 4.13
500 nM Mmp-25 siRNA 10 2.50
The wild-type control palatal cultures (n = 10) examined had a cumulative MFS of 4.14 
while the scrambled duplex siRNA negative control group (n = 10) had a MFS of 4.13. 
The palatal culture group treated with 500 nM Mmp-25 siRNA (n = 10) had a MFS of 
2.50, which is a significant decrease based on the Kruskal-Wallis test (P < 0.05). H&E 
staining showed wild-type palate cultures largely fused normally and had little to no 
MEE remaining after 72 h incubation (Figure 10A). Cultures treated with 500 nM control 
siRNA also fused normally and little remained of the MES after 72 h incubation. Cultures 
treated with 500 nM Mmp-25 siRNA exhibited significantly decreased palate shelf fusion 
and persistence of the MEE after 72 h incubation. To verify the changes in the cultures 
could be attributed to a loss of Mmp-25 expression, qRT-PCR and western blot analysis 
was performed on cDNA and protein from treated cultures and compared to the wild-type 
and negative control siRNA groups. Treatment with 500 nM Mmp-25 siRNA resulted in 
significantly decreased levels of both Mmp-25 mRNA (Figure 10D) and protein (Figure 
10E). These results indicate a functional role for Mmp-25 in mouse secondary palate 
formation.  
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Figure 10: (A-C) Representative hematoxylin and eosin-stained E13.0 secondary palate 
sections (8 μm) following 72 h incubation. (A-B) Wild-type and control siRNA palate 
shelves fused normally; scale bar = 10 μm. (C) Palatal cultures treated with 500 nM 
Mmp-25 siRNA displayed significantly decreased fusion and persistence of the medial 
edge epithelium. (D-E) Confirmation of Mmp-25 expression knockdown in palatal 
cultures. (D) Quantitative real-time PCR confirms a significant Mmp-25 mRNA 
knockdown in palatal cultures treated with 500 nM Mmp-25 siRNA using one-way 
analysis of variance (P < 0.05); n = 4 for each group with four replicates per n. Error bars 
indicate standard error of the mean. (E) Western blot analysis demonstrates absence of 
MMP-25 protein in palatal cultures treated with 500 nM Mmp-25 siRNA. Approximately 
10 μg of total protein was separated via sodium dodecyl sulfate poly-acrylamide gel 
electrophoresis and probed with an anti-MMP-25 antibody (Santa Cruz; 1:1000). An anti-
actin antibody was used to assess loading equivalence (Santa Cruz; 1:1000).  
D E
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3.5 Characterization of Mmp-25 Gene Regulation
Preliminary Mmp-25 promoter analysis using the TRED, Homeodomain Resource 
and EPD indicates putative Smad-binding element (SBE) and Hoxa2 binding sequences 
in the proximal promoter of Mmp-25 (Figure 11). Smad2/3 and Smad4 have been 
previously described to preferentially bind to the sequences 5’-GTCT-3’ and 5’-CAGA-
3’ (Zawel et al., 1998; Jonk et al., 1998; Dennler et al., 1998). A Hoxa2 consensus 
binding sequence consisting of 5’-(T/A)GAT(T/G)GA(T/A)(G/C)(G/T/A)-3’ has been 
previously described (Lampe et al., 2004). 
The Mmp-25 proximal promoter contains a 5’-AGATGGGAACA-3’ sequence 
from deoxynucleotide bases -472 to -482 that could be a binding sequence for Hoxa2. 
Mmp-25 mRNA expression from E12.5 to E15.5 in the SPs of wild-type and Hoxa2-/- 
mice was analyzed using qRT-PCR. At E12.5 there is a significant down-regulation of 
Mmp-25 mRNA expression in Hoxa2-/- mice, relative to the wild-type mice, before Mmp-
25 mRNA expression recovers (Figure 12). This significant difference between wild-type 
and Hoxa2-/- gene expression at E12.5 in the mouse SP is seen with several other genes 
(Smith and Nazarali, unpublished data). 
 Mmp-25 proximal promoter analysis reveals numerous repeats of 5’-GTCT-3’ 
and 5’-CAGA-3’, which are described as being SBEs (Figure 11; Zawel et al., 1998; Jonk 
et al., 1998; Dennler et al., 1998). As the Smad proteins are intra-cellular mediators of 
TGFβ3 signaling, Mmp-25 could be transcriptionally regulated by TGFβ3. Treatment of 
in vitro palatal cultures with 5μg/ml, 10μg/ml or 25μg/ml of a TGFβ3-neutralizing 
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antibody revealed that Mmp-25 is TGFβ3-regulated. Mmp-25 mRNA is significantly 
decreased relative to wild-type levels when treated with 5μg/ml of neutralizing antibody 
Figure 11: The Mmp-25 proximal promoter sequence from -1000 to +100 base pairs 
relative to the transcription start site. Possible Smad-binding element sequences are 
highlighted in yellow and green; a possible Hoxa2 binding sequence is highlighted in 
grey. The transcription start site is underlined and bolded.
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Figure 12: Quantitative real-time PCR of Mmp-25 mRNA expression in the mouse 
secondary palate of wild-type and Hoxa2-/- mice. Mmp-25 mRNA levels are significantly 
decreased at embryonic day 12.5 in the Hoxa2-/- mice using Student’s t-test (P < 0.05). N 
= 4 for all groups with four replicates per N; error bars indicate standard error of the 
mean as confirmed by qRT-PCR (Figure 13A); a sharp decrease in MMP-25 protein 
levels is also observed relative to wild-type (Figure 13B). There was no further decrease 
in Mmp-25 mRNA or protein levels between the 5μg/ml, 10μg/ml or 25μg/ml treated 
groups. To assess the efficacy of the TGFβ3-neutralizing antibody treatments, western 
blot analysis was done on protein samples from all groups with an antibody against 
phospho-Smad1. Levels of phospho-Smad1 decreased as the concentration of the TGFβ3-
E12.5 E13.5 E14.5 E15.5
0
1
2
3
Wild-type
Hoxa2-/-
Developmental Stage
Fo
ld *
63
neutralizing antibody increased (Figure 13C). These results indicate Mmp-25 expression 
is downstream of the growth factor, TGFβ3.      
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Figure 13: (A-B) Quantitative real-time PCR (qRT-PCR) and western blot analysis 
confirm Mmp-25 mRNA and protein levels decrease after treatment with a TGFβ3-
neutralizing antibody in embryonic day (E) 13.0 in vitro palatal cultures following 24 h 
incubation. (A) qRT-PCR shows a significant decrease in Mmp-25 mRNA in in vitro 
palatal cultures using one-way analysis of variance following TGFβ3-neutralizing 
antibody treatment (P < 0.05). N = 4 for all groups with four replicates per N; error bars 
indicate standard error of the mean. (B) Western blot analysis shows a decrease in MMP-
25 protein that parallels the drop in Mmp-25 mRNA expression. Approximately 10 μg of 
total protein was separated via sodium dodecyl sulfate poly-acrylamide gel 
electrophoresis (SDS-PAGE) and probed with an anti-MMP-25 antibody (Santa Cruz; 
1:1000). An anti-β-actin antibody was used to assess loading equivalence (Santa Cruz; 
1:1000). (C) Western blot analysis against phospho-Smad1 shows a TGFβ3-neutralizing 
antibody concentration-dependent effect, demonstrating the drop in Mmp-25 mRNA and 
protein expression is due to a lack of TGFβ3 signaling. Approximately 10 μg of total 
protein was separated via SDS-PAGE and probed with an anti-phospho-Smad1 antibody 
(Cell Signaling Technology; 1:500). An anti-β-actin antibody was used to assess loading 
equivalence (Santa Cruz; 1:1000). 
4. Discussion
4.1 Mmp-25 mRNA and protein is expressed in the developing SP at all stages 
and has a functional role in mouse secondary palate development
Mmp-25 mRNA expression in the embryonic mouse SP at all developmental 
stages was confirmed through qRT-PCR (Figure 8A). Expression of Mmp-25 mRNA 
rises from E12.5 to E13.5, where its expression is strongest, before decreasing at E14.5 
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and even further by E15.5. Mmp-25 mRNA levels are significantly decreased at E15.5 
relative to E12.5 and E13.5 (P < 0.05). At E12.5 and E13.5 the palate shelves are budding 
from the maxilla and growing downward alongside the tongue. At E15.5 the palate 
shelves have fused and the MES is degrading as the SP finishes forming. The increased 
expression of Mmp-25 at E12.5 and E13.5 suggests a role for MMP-25 in promoting 
palate shelf growth as a slight decline in Mmp-25 expression is seen as the shelves are 
fusing (E14.5) and a further significant decline as the MES is degrading (E15.5). Western 
blot analysis indicates MMP-25 protein expression levels parallel mRNA levels in the 
embryonic mouse SP (Figure 8B). MMP-25 appears as a band of approximately 55 kDa, 
which corresponds to previously published reports of a 57 kDa molecular weight for 
MMP-25 (Kang et al., 2001; Kuula et al., 2008; Sun et al., 2007). 
Immunohistochemical staining indicates MMP-25 protein localizes more strongly 
to the epithelium of the palate shelves rather than the underlying mesenchyme (Figure 9). 
At E12.5 and E13.5 the strongest immunofluoresence can be detected in the epithelium of 
the palate shelves with secondary expression in portions of the mesenchyme immediately 
adjacent to the epithelium. These two stages represent continued palate shelf growth 
alongside the tongue before the shelves elevate and make contact along their medial 
edges. Secondary expression of MMP-25 protein in the mesenchyme appears to be much 
more apical on the leading edge of palate shelf growth rather than deeper into the interior 
of the palate shelf (Figure 9I, J). At E14.5 the palate shelves are fusing along their medial 
edges and immunofluoresence shows strong MMP-25 expression in the epithelium of the 
palate shelves, but secondary expression in the underlying mesenchyme appears much 
more scattered as opposed to the focused mesenchymal expression at E12.5 and E13.5 
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(Figure 9G, K). It is possible that this decrease in focused mesenchymal expression in the 
apical palate shelf is due either to the focus moving from growth to fusion in SP 
development at E14.5 or to the new horizontal orientation of the palate shelves, which 
still require some growth at E14.0 to make contact after elevation prior to fusion. At 
E15.5 the MES is degrading and there is little epithelium left between the two palate 
shelves. MMP-25 immunofluoresence at this stage is noticeably weaker than that from 
E12.5 to E14.5, but continues to be primarily epithelial as evidenced by the 
immunofluoresence of the oral epithelium and a degrading remnant of the MES (Figure 
9H, L). This drop in MMP-25 immunofluoresence at E15.5 coincides with a confirmed 
drop in Mmp-25 mRNA and protein levels, however mesenchymal expression appears to 
be stronger at E15.5 than any other stage and mesenchymal expression is more dispersed 
rather than localized to apical areas adjacent to epithelium as from stages E12.5 and 
E13.5 (Figure 9L). At all stages MMP-25 immunofluoresence in the SP localized to the 
area around the plasma membranes of the epithelial and mesenchymal cells, which is 
expected as MMP-25 is a MT-MMP (Kojima et al., 2000). The data collected supports 
the hypothesis that MMP-25 is expressed in the MEE, but seems to disagree with the 
hypothesis of MMP-25 having a role during degradation of the MES as IHC results point 
to decreased MMP-25 expression during this stage; however protein expression of MMP-
25 is not significantly decreased at E14.5 relative to the highest levels at E13.5 so MMP-
25 could still be involved in fusion of the palate shelves. The data indicating strongest 
MMP-25 protein expression in apical areas of palate shelf growth from E12.5 and E13.5 
suggest MMP-25 plays a role in facilitating this growth by removing ECM barriers to 
increased cell proliferation and movement and, possibly, by activating pro-MMPs that 
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could do the same (Nie and Pei, 2003). Location and timing of the strongest 
immunofluorescence would suggest MMP-25 might be acting through its traditional role 
as a protease and removing ECM barriers to increased palate shelf growth. 
To determine if MMP-25 is playing a functional role during mouse SP formation, 
Mmp-25 mRNA expression was knocked down in vitro using Mmp-25 siRNA and whole 
SP cultures as previously described (Shiomi et al., 2006; Nakajima et al., 2007). Addition 
of Stealth™ RNAi Mmp-25 siRNA (Invitrogen) to a final concentration of 500 nM 
resulted in decreased palate shelf fusion and persistence of the MEE in vitro as evidenced 
by representative hematoxlyin and eosin-stained palatal sections (Figure 10A-C). 
Whereas the wild-type and negative control siRNA palatal cultures fused normally, the 
palatal cultures treated with Mmp-25 siRNA seemed largely unable to progress to the 
fusion stage even though they were contacting one another. Interestingly, the phenotype 
of the Mmp-25 siRNA-treated palatal cultures (Figure 10C) after 72 h incubation is very 
similar to the phenotype of other in vitro palatal cultures treated with a general chemical 
inhibitor of the MMPs (Blavier et al., 2001). To obtain a more objective measure of the 
Mmp-25 siRNA effects, serial sections (8 μm) of preserved and frozen palatal cultures 
were generated. Every 8th section was examined by light microscopy and up to 15 
sections were examined in total. Each section was given a score based on the 
completeness of fusion and quantity of remaining epithelium where 1 indicates no contact 
between the palate shelves and 5 indicates complete fusion (Kang and Svoboda, 2002). 
For each palatal culture thus examined the scores were combined and averaged to obtain 
a mean fusion score (MFS) and these MFSs could themselves be averaged for an entire 
group. The results of the in vitro palatal cultures are displayed in Table 2. The wild-type 
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control palatal cultures (n = 10) examined had a cumulative MFS of 4.14 while the 
scrambled duplex siRNA negative control group (n = 10) had a MFS of 4.13. This puts 
both groups solidly in the fusion category and shows absolutely minimal non-specific 
siRNA or transfection reagent effects. The palatal culture group treated with 500 nM 
Mmp-25 siRNA (n = 10) had a MFS of 2.50, which is a significant decrease based on the 
Kruskal-Wallis test (P < 0.05). To ensure the drop in MFS could be attributed to an 
Mmp-25 mRNA and subsequent protein knockdown, quantitative real-time PCR and 
western blot analysis was carried out on total RNA and protein isolated from the 
remaining palatal cultures of each group. The Mmp-25 siRNA did knockdown both 
Mmp-25 mRNA and protein levels efficiently. A significant decrease in Mmp-25 mRNA 
levels in the Mmp-25 siRNA-treated group was found relative to the control groups using 
qRT-PCR (Figure 10D; P < 0.05) and western blot analysis displayed a sharp reduction in 
MMP-25 protein levels in the treated group when compared to the control groups (Fig. 
10E). Taken together, these data suggest MMP-25 does have a functional role in mouse 
SP development and validate my hypothesis that Mmp-25 knockdown would significantly 
inhibit palate shelf fusion and cause the MEE to persist.  
Overall, little is still known about MMP-25 developmentally or the relationship 
between the MMPs and palatogenesis. Expression of Mmp-25 is highest at stages 
corresponding to palate shelf growth and immunofluoresence localizes this expression to 
apical epithelial and mesenchymal areas of the palate shelves. Between the epithelial and 
mesenchymal portions of the palate shelves lies the basement membrane (BM), in 
addition to the ECM surrounding these cells in all other dimensions. Cell proliferation 
and migration in the palate shelves is impossible with cells solidly adhering to the BM. 
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The primary structural component of the BM is type IV collagen, which is unique to the 
BM and provides a scaffold for other proteins within the BM (Kühn, 1995); MMP-25 
cleaves type IV collagen very efficiently (English et al., 2001), but also fibrin and 
fibronectin, which are important BM proteins (Kang et al., 2001). Fibrin binds to and is 
assembled primarily by type IV collagen (Jones and Gabriel, 1988) so not only can 
MMP-25 cleave fibrin, but loss of type IV collagen through MMP-25 cleavage will 
further weaken the BM through loss of an anchoring point for fibrin assembly. 
Fibronectin is a key BM protein that binds to α5β1-integrin embedded in the plasma 
membranes of epithelial cells in apical areas of the palate shelves (Martìnez-Sanz et al., 
2008). It is possible MMP-25 targets fibronectin for degradation in the apical epithelium 
during palate shelf growth or expression of Mmp-25 depends on fibronectin/integrin 
binding. Expression of MMP-13 and MMP-14 is dependent on α1β1-integrin in 
endochondral development (Ronzière et al., 2005) and α5β1-integrin in joint cartilage 
formation (Forsyth et al., 2002) while MMP-14 expression is downstream of both 
fibronectin and α4/α5β1-integrin dimers (Manduca et al., 2009), but nothing is currently 
known about the role of integrins or fibronectin in modulating expression of Mmp-25 in 
general or in SP formation. The strongest evidence to support a role for MMP-25 in 
facilitating palate shelf growth comes from MT-MMP knockout mouse models. 
Mmp-14-/- (MT1-MMP) mice have significant developmental defects related to a 
decrease in skeletal cell proliferation caused by an inability of bone-specific cells to reach 
sites of proliferation (Holmbeck et al., 1999; Zhou et al., 2000). Mmp-16-/- (MT3-MMP) 
mice are largely normal, but Mmp-16-/- mice that are also Mmp-14-/- exhibit significant 
skeletal defects similar to those of the Mmp-14-/- mice; the double knockout mice also 
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develop a complete CP, which does not occur in the single Mmp-14-/- mice (Shi et al., 
2008). Improper SP development in the double knockout mice was the result of impaired 
palate shelf growth due to a decrease in mesenchymal cell proliferation, although the tiny 
palate shelves elevated normally (Shi et al., 2008). This is significant evidence to support 
my contention that the MT-MMPs are indispensable to palate shelf growth by removing 
ECM barriers to proliferation. A lack of CP in Mmp-14-/- mice could be due to MMP-25 
functionally substituting for MMP-14 in the SP just as MMP-14 can substitute for MMP-
16 in SP development (Shi et al., 2008).      
4.2 Mmp-25 is a downstream transcriptional target of TGFβ3  
It has been known for some time that the secreted growth factor, TGFβ3, is vital 
to the successful formation of the mouse SP (Kaartinen et al., 1997; Taya et al., 1999). 
TGFβ3 exerts biological activity through its receptors, which are tyrosine kinases, and 
intra-cellular mediators, the Smad proteins, which translocate to the nucleus affecting 
gene transcription following phosphorylation (Chai et al., 2003). A brief examination of 
the proximal promoter sequence of Mmp-25 obtained from the EPD displayed repeating 
sequences of 5΄-GTCT-3΄ and 5΄-CAGA-3΄, which have been demonstrated to be sites of 
preferential binding by the Smad proteins (Dennler et al., 1998; Jonk et al., 1998; Zawel 
et al., 1998). Because of their existence just upstream of the Mmp-25 transcription start 
site, it was hypothesized Mmp-25 could be a transcriptional target of TGFβ3 signaling. A 
TGFβ3-neutralizing antibody (R&D Systems) was added to in vitro palatal cultures to 
final concentrations of 0 μg/ml (wild-type control), 5 μg/ml, 10 μg/ml and 25 μg/ml and 
incubated for 24 h. Following incubation, qRT-PCR and western blot analysis was 
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carried out on total pooled RNA and protein isolated from each group. Preliminary 
analysis into a link between TGFβ3 and Mmp-25 showed Mmp-25 mRNA and protein 
levels are significantly decreased (P < 0.05) following 24 h incubation with 5 μg/ml of a 
TGFβ3-neutralizing antibody (Figure 13A,B). There was no significant difference in 
Mmp-25 mRNA or protein levels between the groups treated with different 
concentrations of the TGFβ3-neutralizing antibody. To make sure the decrease in Mmp-
25 mRNA and protein could be attributed to a loss of TGFβ3 activity in the cultures, 
western blot analysis was carried out on total protein isolated from the four groups with a 
phospho-Smad1 antibody. Levels of phospho-Smad1 were inversely correlated with the 
concentration of the TGFβ3-neutralizing antibody; as the bioneutralizing antibody 
concentration went up, phospho-Smad1 levels went down (Figure 13C). A link between 
the MMPs and TGFβ3 is not without precedent; MMP-13 expression has been 
demonstrated to be downstream of TGFβ3 (Blavier et al., 2001) as has expression of the 
gelatinases, MMP-2 and -9 (Greene et al., 2003). Expression of MMP-9 can also be 
suppressed by TGFβ3 via a Smad7/NF-κB-dependent pathway (Ogawa et al., 2004). 
Mice, which are Tgfβ3-/-, have smaller palate shelves that elevate, but never grow together 
and make contact along their medial edges (Kaartinen et al., 1997). These data suggest 
MMP-25 is a direct transcriptional target for TGFβ3 in the mouse SP and support my 
final hypothesis that Mmp-25 would be transcriptionally regulated by TGFβ3.  
 5. Future Directions 
The development of an Mmp-25-/- mouse will be a huge step toward uncovering 
the role of MMP-25 in mouse embryonic development. It is certainly possible that Mmp-
25-/- mice will have similar, post-natal lethal developmental defects that Mmp-14-/- mice 
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display. Regarding SP development, generation of Mmp-25-/- mice will allow an in vivo 
examination of the role of MMP-25 in palate shelf growth and whether alternate MT-
MMPs can functionally substitute partially or wholly for MMP-25 in SP development. 
This is work not possible with an in vitro palatal culture system. Another possible avenue 
is an identification of MMP-25 substrates in the mouse SP. Is MMP-25 cleaving type IV 
collagen, fibronectin or fibrin in the BM? These are known substrates in other tissues, but 
may not be in the SP. Histological analysis and comparison of the developing SP between 
wild-type and Mmp-25-/- mice could determine whether MMP-25 is cleaving these 
substrates. 
MMP-25 is efficiently inhibited by TIMP-2 and -3 and strongly inhibited by 
TIMP-1 (English et al., 2001). Does increased Mmp-25 expression during SP 
development positively correlate with increased expression of one or more of the TIMPs? 
Is there any manner of temporal or spatial regulation in TIMP expression in the SP as it 
forms? Future work regarding MMP-25 in the SP could be directed at the relationship 
between these TIMPs and MMP-25 during SP development. 
An association between Mmp-25 gene transcription and TGFβ3 has been 
established. This link could be further strengthened by work demonstrating direct 
association between Smad2/3 and Smad4 and the Mmp-25 promoter such as chromatin 
immunoprecipitation or electrophoretic mobility shift assays. A more in-depth 
examination of the Mmp-25 promoter could identify additional regulatory molecules. 
Cloning of the Mmp-25 promoter and insertion into an expression construct upstream of a 
reporter gene could help verify if the molecules identified in the promoter examination 
are actually controlling Mmp-25 expression.     
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6. Conclusions
MMP-25 mRNA and protein is expressed in the developing mouse SP and protein 
expression largely localizes to the epithelium of the palate shelves. Expression of MMP-
25 mRNA and protein is highest at E13.5 and there is a significant decrease in mRNA 
levels by E15.5. Immunohistochemical analysis of MMP-25 protein expression has 
shown MMP-25 protein is most abundant in the epithelium of the palate shelves with 
secondary expression in the underlying mesenchyme. Expression in the mesenchyme 
occurs in apical areas adjacent to the over-lying epithelium at E12.5 and E13.5, but 
becomes much more scattered by E14.5 and E15.5.  
Through use of palatal cultures, it has been shown treatment with an MMP-25-
specific siRNA decreases palate shelf fusion and results in significant persistence of MEE 
in vitro. This is the first evidence to support a functional role for a single MMP in mouse 
SP development. This in vitro palatal culture work coupled with the 
immunohistochemical and real-time PCR data suggests MMP-25 plays a key role in 
palate shelf growth at E12.5 and E13.5 by removing ECM barriers that would hinder cell 
proliferation and movement. The substrates of MMP-25 include type IV collagen, 
fibronectin and fibrin, which are all components of the BM and barriers to cell 
proliferation and movement; immunohistochemical analysis of MMP-25 protein 
expression in colorectal tissue sections shows MMP-25 is strongly expressed on the 
leading edge of tumours and positively correlates to an invasive cancer. These results 
indicate MMP-25 protein expression in the developing mouse SP is also strongest on the 
apical, or leading, edge. Most compellingly, double knock-out of MMP-14 (MT1-MMP) 
and MMP-16 (MT3-MMP) results in a cleft palate in mice due to impaired growth of the 
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palate shelves, which implies a role for proteolytic enzymes in mouse SP development 
even though there were no palate defects reported for the single gene knock-out of MMP-
16 or MMP-14. These results indicate MMP-25 is a key proteolytic enzyme among the 
MMPs during mouse SP formation.
In addition to the results on MMP-25 gene expression and functional importance 
during mouse SP development, a link between MMP-25 and TGF-β3 in the developing 
mouse SP has been established; this is the first research to detail the transcriptional 
regulation of Mmp-25, however it is preliminary and warrants further investigation. 
Treatment of whole palatal cultures with a TGF-β3-neutralizing antibody in the culture 
medium resulted in a significant decrease in MMP-25 mRNA and protein. Given the 
steep decrease in both mRNA and protein levels, it would seem that MMP-25 is a direct 
target of TGF-β3 during mouse SP development.
Overall, nothing is known about the role of Mmp-25 in embryonic development. 
This work represents the first research into a developmental role for MMP-25, in this 
case the mouse SP. These results are compelling and need further research to more 
clearly outline the role of MMP-25 in SP development.         
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Appendix A
PCR Primer Design and Analysis Software    
Primer3:  http://frodo.wi.mit.edu/
NetPrimer:  http://www.premierbiosoft.com/netprimer/netprlaunch/netprlaunch.html
  
Multiple Sequence Alignment Software
ClustalW:  http://www.ebi.ac.uk/clustalw/
BLASTn:  http://www.ncbi.nlm.nih.gov/BLAST/
Promoter Analysis Software
Eukaryotic Promoter Database: http://www.epd.isb-sib.ch/
96
Homeodomain Resource: http://research.nhgri.nih.gov/homeodomain/
TRED:  http://rulai.cshl.edu/cgi-bin/TRED/tred.cgi?process=home
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